{"gene":"PRDX2","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":2000,"finding":"Crystal structure of human decameric peroxiredoxin 2 (TPx-B/PRDX2) from erythrocytes was determined at 1.7 Å resolution, revealing a toroid of five head-to-tail homodimers; the active-site Cys51 was oxidized to cysteine sulphinic acid, trapping a stable decamer, and the structure demonstrated that the catalytic cycle requires significant conformational changes including unwinding of the active-site helix and movement of four loops.","method":"X-ray crystallography, sedimentation analysis","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional validation by sedimentation","pmids":["10873855"],"is_preprint":false},{"year":2002,"finding":"Proteomics analysis of oxidative stress responses showed that the peroxiredoxin active-site cysteine of PRDX2 is overoxidized in vivo to cysteic acid, inactivating the enzyme; the balance of oxidized vs. native PRDX2 plays an active role in resistance or susceptibility to TNF-α-induced apoptosis in Leydig cells.","method":"2D gel proteomics, tandem mass spectrometry, cell-based apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — MS-based identification of in vivo modification with functional apoptosis readout","pmids":["11904290"],"is_preprint":false},{"year":2003,"finding":"PRDX2 is under-expressed in Down syndrome fetal brains; stable antisense knockdown of PRDX2 in SH-SY5Y neuroblastoma cells increased sensitivity to oxidative stress and apoptosis under basal conditions and after oxidative challenge, at levels comparable to the effect of SOD1 overexpression, demonstrating PRDX2's non-redundant role in neuronal redox defense.","method":"Suppression subtractive hybridization, real-time PCR, stable antisense transfection, cell viability and apoptosis assays","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — knockdown with specific phenotypic readout in single lab","pmids":["12943237"],"is_preprint":false},{"year":2004,"finding":"Reactive oxygen species elevated by PRDX2 (PrxII) gene deletion in mice led to enlarged thymus with increased thymocyte numbers; PrxII-null thymocytes showed reduced hypodiploid cell formation and resistance to apoptosis induced by dexamethasone or food restriction, establishing PRDX2 as a regulator of thymocyte survival and maturation through ROS control.","method":"PrxII knockout mouse model, FACS analysis of thymocyte subsets, apoptosis assays, proliferation assays","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — in vivo knockout with multiple orthogonal phenotypic readouts","pmids":["15259009"],"is_preprint":false},{"year":2004,"finding":"Sestrins, whose expression is modulated by p53, are required for regeneration (reduction) of hyperoxidized peroxiredoxins including PRDX2; purified Hi95 (sestrin 2) supports ATP-dependent reduction of overoxidized Prx in vitro, functioning as a cysteine sulfinyl reductase (not a disulfide reductase), thereby reestablishing the antioxidant capacity of PRDX2 after H2O2-mediated overoxidation.","method":"In vitro reconstitution with purified proteins, cell-based assays, bioinformatics","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with purified protein, multiple supporting cell-based experiments","pmids":["15105503"],"is_preprint":false},{"year":2005,"finding":"PRDX2 (Prx II) is a negative regulator of PDGF receptor signaling: it is recruited to PDGFR upon PDGF stimulation and locally eliminates H2O2 produced in response to PDGF, thereby suppressing protein tyrosine phosphatase inactivation. PRDX2 deficiency results in enhanced H2O2 production, enhanced PDGFR and PLCγ1 activation, increased VSMC proliferation/migration, and PDGF-dependent neointimal thickening in a murine restenosis model.","method":"Prdx2 knockout mouse, co-immunoprecipitation (PDGFR-PRDX2 interaction), cell proliferation/migration assays, murine restenosis model, in vitro peroxidase activity (inactive mutant comparison)","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal Co-IP, knockout mouse, inactive mutant control, in vivo model, replicated across multiple assays","pmids":["15902258"],"is_preprint":false},{"year":2006,"finding":"PRDX2 functions as a noncatalytic scavenger of low-level hydrogen peroxide in human erythrocytes: it is extremely sensitive to oxidation (dimerization observed at 0.5 µM H2O2), resistant to overoxidation (due to very low thioredoxin reductase activity limiting recycling), and is oxidized by endogenously generated H2O2 from hemoglobin autoxidation, demonstrating its role in erythrocyte defense is stoichiometric rather than enzymatic.","method":"H2O2 treatment of erythrocytes, non-reducing SDS-PAGE dimerization assay, thioredoxin reductase activity measurement, hemolysate experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical assays with multiple orthogonal methods, mechanistically rigorous","pmids":["17105810"],"is_preprint":false},{"year":2007,"finding":"PRDX2 peroxidase activity is highly selective for H2O2 and organic hydroperoxides (rate constant ~1.3 × 10^7 M^-1 s^-1 for H2O2), but reacts extremely slowly with amino acid chloramines and the alkylating agent iodoacetamide, demonstrating that its tertiary structure facilitates H2O2 reactivity while restricting reactivity with other thiol reagents.","method":"Competition kinetics with horseradish peroxidase, non-reducing SDS-PAGE dimerization inhibition assay, multiple oxidant comparisons","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — rigorous in vitro kinetics with multiple oxidants and controls","pmids":["17329258"],"is_preprint":false},{"year":2007,"finding":"PRDX2 (Prx2) is phosphorylated at Thr89 by Cdk5/p35 in neurons treated with MPP+/MPTP; this phosphorylation reduces Prx2 peroxidase activity. Calpain-mediated Cdk5 activation upstream drives this modification. Expression of phosphorylation-resistant Prx2T89A (but not the phosphomimetic Prx2T89E) protects dopaminergic neurons from mitochondrial toxin-induced death, and Prx2 Thr89 phosphorylation is elevated in nigral neurons of Parkinson's disease patients.","method":"Co-immunoprecipitation (Prx2-Cdk5/p35), site-directed mutagenesis (T89A, T89E), in vitro peroxidase activity assay, MPP+/MPTP neurotoxicity model, p35 knockout neurons, transgenic overexpression, postmortem human brain immunostaining","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1-2 — mutagenesis, in vitro activity assay, Co-IP, KO epistasis, human pathological tissue validation across multiple orthogonal methods","pmids":["17610816"],"is_preprint":false},{"year":2008,"finding":"HDAC6 is a specific deacetylase of PRDX2 (and PRDX1); acetylation of PRDX2 (accumulating when HDAC6 is inactive) increases its H2O2-reducing activity, its resistance to superoxidation, and its resistance to transition to high-molecular-mass complexes, identifying acetylation as a positive regulatory PTM for PRDX2 enzymatic function.","method":"HDAC6 knockout/inhibition, immunoprecipitation, in vitro deacetylase assay, H2O2 reduction activity assay, hyperoxidation resistance assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — identification of writer/eraser enzyme with functional activity assays and multiple readouts","pmids":["18606987"],"is_preprint":false},{"year":2009,"finding":"Cytoplasmic Cdk5 is critically activated in stroke models (focal and global ischemia) in vivo, and PRDX2 (Prx2) is a critical cytoplasmic target of Cdk5; expression of dominant-negative Cdk5 localized to the cytoplasm is neuroprotective, and manipulation of Prx2 modulates neuronal survival after ischemic insult, establishing the calpain→Cdk5→Prx2 phosphorylation axis in ischemic neuronal death.","method":"Focal and global stroke mouse models, compartment-specific dominant-negative Cdk5 constructs, subcellular fractionation, Prx2 manipulation, neuronal death quantification","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — in vivo epistasis with compartmentalized constructs, multiple ischemia models","pmids":["19812325"],"is_preprint":false},{"year":2011,"finding":"In human erythrocytes, PRDX2 (PrxII) exists in four distinct oligomeric states in the cytosol: a 440 kDa hetero-oligomeric complex with tetrameric catalase, and homo-polymeric complexes at 140, 100, and 67 kDa. Under oxidative stress (28-day storage), the 100 kDa complex disappears, the catalase-PrxII complex shifts to 480 kDa (incorporating cross-linked hemoglobin), and oxidized PrxII translocates to the membrane. Peroxidase activity was demonstrated for the 440 kDa and 140 kDa oligomers.","method":"Native proteomics (2D-DIGE, BN-PAGE), mass spectrometry, size-exclusion chromatography, peroxidase activity assay, fractionation of cytosol vs. membrane","journal":"Biochimie","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal proteomics methods identifying novel complex with activity validation","pmids":["21354257"],"is_preprint":false},{"year":2014,"finding":"PRDX2 forms a redox relay with transcription factor STAT3: PRDX2 acts as an H2O2 signal receptor (reacting at ~10^7–10^8 M^-1 s^-1) and transmitter, oxidizing STAT3 via disulfide exchange to generate disulfide-linked STAT3 oligomers with attenuated transcriptional activity. Cytokine-induced STAT3 signaling is accompanied by co-oxidation of PRDX2 and STAT3, and is modulated by PRDX2 expression levels.","method":"Co-immunoprecipitation, non-reducing SDS-PAGE, in vitro redox reconstitution, siRNA knockdown/overexpression, cytokine stimulation, reporter assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro reconstitution of relay, Co-IP, mutagenesis context, functional transcriptional readout replicated across multiple approaches","pmids":["25402766"],"is_preprint":false},{"year":2014,"finding":"Inflammatory stimuli (LPS) induce release of glutathionylated PRDX2 from macrophages; extracellular glutathionylated PRDX2 acts as a redox-dependent danger signal triggering macrophages to produce TNF-α. PRDX2 is constitutively present intracellularly in reduced form and is released in oxidized (glutathionylated) form upon LPS stimulation. Co-released thioredoxin enables an oxidative cascade modifying surface receptor -SH groups to facilitate inflammatory activation.","method":"Mass spectrometry proteomic identification of glutathionylated proteins in LPS-stimulated macrophage conditioned medium, ELISA for TNF-α, Western blot, LPS stimulation of multiple cell types","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — MS identification of specific modification plus functional cytokine readout across multiple cell types","pmids":["25097261"],"is_preprint":false},{"year":2015,"finding":"Peroxynitrite-mediated nitration of PRDX2 on non-catalytic tyrosines causes the reduced nitrated enzyme to adopt a conformation resembling the disulfide-oxidized native form, facilitating disulfide bond formation; this structural change explains the previously observed increase in peroxidase activity and resistance to overoxidation of nitrated PRDX2.","method":"Analytical ultracentrifugation, UV absorption, circular dichroism, steady-state and time-resolved fluorescence of recombinant human PRDX2","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 — multiple biophysical methods on purified protein with structural-functional correlation","pmids":["26612102"],"is_preprint":false},{"year":2018,"finding":"Among interphase CDKs, CDK2 is specifically degraded via ubiquitin-proteasome pathway (with KLHL6 as E3 ligase) during AML differentiation; CDK2 depletion reactivates the differentiation pathway in part by reducing its direct maintenance of PRDX2 activity. The CDK2-PRDX2 axis maintains the differentiation block in AML cells.","method":"Yeast 2-hybrid (CDK2-KLHL6 interaction), ubiquitination assays, CDK2 inhibition/knockdown, AML differentiation assays (cell lines and primary patient samples), PRDX2 activity measurement, xenograft mouse models","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — yeast 2-hybrid plus functional analysis, but CDK2-PRDX2 direct mechanism not biochemically reconstituted","pmids":["29720484"],"is_preprint":false},{"year":2018,"finding":"Kinetic analysis shows that PRDX2 (unlike PRDX1) has a slow rate of intramolecular disulfide formation during catalytic cycle (0.2 s^-1 vs 11 s^-1 for PRDX1), creating a longer-lived sulfenic acid intermediate; this kinetic pause allows PRDX2's peroxidatic cysteine sulfenic acid to react with other protein thiols to transmit redox signals via mixed disulfides, differentiating its signaling role from PRDX1.","method":"In vitro kinetics using recombinant human PRDX1 and PRDX2, intrinsic fluorescence monitoring of oxidation and hyperoxidation with H2O2 and peroxynitrite","journal":"Protein science","confidence":"High","confidence_rationale":"Tier 1 — rigorous in vitro kinetics with purified recombinant proteins establishing mechanistic distinction","pmids":["30284335"],"is_preprint":false},{"year":2018,"finding":"Radioprotective effects of exogenous recombinant PRDX2 in X-ray-irradiated animals are mediated by its peroxidase activity, its chaperone activity in the oxidized state (preventing protein misfolding and aggregation), and signal-regulatory functions via H2O2 level modulation; exogenous PRDX2 reduces ROS, suppresses apoptosis, prevents leukopenia/thrombocytopenia, and protects bone marrow DNA.","method":"Whole-body X-ray irradiation in vivo model, recombinant PRDX2 administration, survival studies, ROS measurement, apoptosis assays, bone marrow DNA damage assays","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo model with multiple phenotypic readouts, single lab","pmids":["30605715"],"is_preprint":false},{"year":2018,"finding":"DNMT3A-R882H/C mutations in AML upregulate PRDX2 expression through promoter hypomethylation; elevated PRDX2 decreases ROS accumulation and reduces apoptosis, promoting leukemogenesis. Both DNMT3A-WT and R882H/C mutants physically interact with PRDX2. Knockdown of PRDX2 from DNMT3A-mutant myeloid cells restores drug sensitivity and apoptosis.","method":"Co-immunoprecipitation (DNMT3A-PRDX2 interaction), DNA methylation assay, gene expression profiling, PRDX2 knockdown, ROS measurement, apoptosis assays","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP plus functional knockdown, single lab","pmids":["30245403"],"is_preprint":false},{"year":2019,"finding":"REV7, the structural subunit of DNA polymerase ζ, interacts with PRDX2 and recruits it to nuclear foci at DNA double-strand breaks post-irradiation; REV7 knockdown disrupts nuclear PRDX2 localization, causing increased oxidative stress and unrepaired DSBs, establishing a REV7-PRDX2 complex that confers radioresistance by protecting against oxidative stress at DSBs.","method":"Proteomic analysis of REV7-interacting proteins, co-immunoprecipitation, immunofluorescence co-localization, REV7 knockdown/overexpression, ROS measurement, γH2AX (DSB) assay, xenograft model","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP plus co-localization plus functional knockdown with mechanistic readout","pmids":["30657231"],"is_preprint":false},{"year":2019,"finding":"H. pylori infection activates NF-κB which transcriptionally upregulates PRDX2 (NF-κB-p65 binding site on PRDX2 promoter confirmed by luciferase reporter and ChIP assays); PRDX2 knockdown in gastric cancer cells increases ROS, oxidative DNA damage, and double-strand breaks in response to H. pylori, and sensitizes cells to cisplatin treatment.","method":"Luciferase reporter assay, ChIP assay, PRDX2 knockdown (shRNA), H2DCFDA ROS assay, 8-oxoguanine, γH2AX, in vitro and in vivo H. pylori infection models","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP + reporter identifies transcriptional mechanism; functional KD with multiple molecular readouts replicated in vitro and in vivo","pmids":["31536951"],"is_preprint":false},{"year":2020,"finding":"PRDX2 removal in colorectal cancer cells by shRNA inhibits S-phase progression and induces autophagy via the p38 MAPK/FOXO signaling pathway; the p38 activator dehydrocorydaline partially rescues cell-cycle and autophagy effects of PRDX2 knockdown, placing PRDX2 upstream of p38 MAPK in cell-cycle control.","method":"shRNA knockdown, flow cytometry (cell cycle), electron microscopy (autophagy), Western blot (p38 activation), immunostaining, p38 activator rescue, xenograft mouse model","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 — shRNA with epistasis rescue and multiple orthogonal readouts, single lab","pmids":["32692719"],"is_preprint":false},{"year":2020,"finding":"PRDX2 overexpression in H9c2 cardiomyocytes promotes TLR4-mediated inflammatory factor expression (IL-1β, TNF-α, IL-6) and VEGF expression under hypoxia while inhibiting ROS-mediated injury, demonstrating a dual role: cytoprotective (ROS scavenging) and pro-inflammatory (via TLR4 pathway activation).","method":"PRDX2 overexpression in H9c2 cells, AMI mouse model, ELISA, immunocytochemistry, immunofluorescence, ROS measurement","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 — overexpression with mechanistic pathway identification, single lab","pmids":["28765537"],"is_preprint":false},{"year":2020,"finding":"PRDX2 inhibits TLR4/NF-κB signaling in myocardial cells after acute myocardial infarction: recombinant PRDX2 treatment in AMI rats decreases ROS, reduces caspase-family expression, inhibits p65 phosphorylation, and suppresses TLR4/NF-κB pathway activity, reducing myocardial apoptosis.","method":"AMI rat model (LAD ligation), recombinant PRDX2 administration, Western blot, qRT-PCR, ROS assay","journal":"Medical science monitor","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo model with recombinant protein and pathway measurement, single lab","pmids":["33268762"],"is_preprint":false},{"year":2021,"finding":"CircDIDO1 specifically binds PRDX2 protein and promotes RBX1-mediated ubiquitination and proteasomal degradation of PRDX2, leading to inactivation of PRDX2 downstream signaling pathways; this reduces gastric cancer cell proliferation, migration, and invasion.","method":"Tagged RNA affinity purification, mass spectrometry, co-immunoprecipitation, immunofluorescence, Western blot, gain/loss-of-function studies, xenograft mouse models","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 — RNA-protein interaction identified by TRAP-MS + Co-IP ubiquitination validation, single lab","pmids":["34384442"],"is_preprint":false},{"year":2021,"finding":"PRDX2 overexpression in vascular smooth muscle cells reduces ROS (H2O2), collagen I/III, VCAM-1, and ICAM-1 expression, and inhibits VSMC proliferation, migration, and phenotype transformation; PRDX2 suppresses p-p38, p-JNK, and p-ERK activation (MAPK pathway), providing protection against atherosclerosis. MAPK inhibitor treatment confirmed the mechanistic link.","method":"PRDX2 overexpression/siRNA knockdown in CAVSMCs, MAPK inhibitors (SB203580, SP600125, PD98059), proliferation/migration assays, Western blot, immunostaining","journal":"Frontiers in cardiovascular medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological epistasis plus gain/loss of function, single lab","pmids":["33791345"],"is_preprint":false},{"year":2022,"finding":"Oxiconazole downregulates PRDX2 protein levels to initiate autophagy in colorectal cancer cells by inactivating the Akt/mTOR pathway and inhibiting RAB7A-mediated autophagosome-lysosome fusion, causing extreme accumulation of autophagosomes; PRDX2 overexpression rescues OXI-induced autophagy arrest, establishing PRDX2 as a critical node upstream of Akt/mTOR in autophagy regulation.","method":"Drug treatment, PRDX2 overexpression rescue, autophagy flux assays, Akt/mTOR pathway Western blot, RAB7A analysis, CRC xenograft model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 — overexpression rescue establishes causal mechanism, single lab","pmids":["35813474"],"is_preprint":false},{"year":2023,"finding":"Dihydromyricetin (DHM) induces neuroprotection after subarachnoid hemorrhage through a Nrf2-dependent increase in PRDX2 expression that decreases phosphorylation of p38 and ASK1; siRNA knockdown of Prx2 or Nrf2 inhibition with ML385 attenuates DHM's neuroprotective effects, placing PRDX2 downstream of Nrf2 in the anti-oxidative cascade triggered by DHM.","method":"SAH rat model, siRNA knockdown of Prx2, Nrf2 inhibitor ML385, neurological behavioral tests, ROS assay, Western blot, immunofluorescence, primary cortical neurons in vitro","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo + in vitro epistasis with siRNA and pharmacological inhibitor, single lab","pmids":["37523836"],"is_preprint":false}],"current_model":"PRDX2 is a cytosolic typical 2-Cys peroxidase that forms a decameric toroid of five homodimers and scavenges H2O2 with exceptionally high reactivity (~10^7 M^-1 s^-1) via its peroxidatic Cys51; its slower intramolecular disulfide formation rate (vs. PRDX1) prolongs the sulfenic acid intermediate, enabling it to transmit redox signals through mixed disulfides to partners such as STAT3, and its activity is regulated by multiple PTMs including Cdk5-mediated phosphorylation at Thr89 (inactivating), HDAC6-dependent deacetylation (modulating activity/overoxidation resistance), and peroxynitrite-mediated tyrosine nitration (activating); it is recruited to PDGFR to locally suppress H2O2-dependent signaling, released as glutathionylated PRDX2 to trigger inflammatory TNF-α responses, and its oxidized form exhibits chaperone activity, while overoxidized PRDX2 is regenerated by p53-regulated sestrins."},"narrative":{"teleology":[{"year":2000,"claim":"Determining the atomic structure of PRDX2 revealed how a decameric toroid architecture positions the catalytic Cys51 and requires large conformational rearrangements during catalysis, establishing the structural framework for understanding its peroxidase mechanism.","evidence":"1.7 Å X-ray crystal structure of human erythrocyte PRDX2 with sedimentation analysis","pmids":["10873855"],"confidence":"High","gaps":["No structure of the reduced active-site form was captured","Dynamics of conformational transitions during catalysis unresolved"]},{"year":2002,"claim":"Identification of in vivo overoxidation of the active-site cysteine to cysteic acid revealed that irreversible inactivation of PRDX2 modulates susceptibility to TNF-α-induced apoptosis, establishing overoxidation as a functionally consequential event rather than an artifact.","evidence":"2D-gel proteomics and tandem MS in Leydig cells with apoptosis readout","pmids":["11904290"],"confidence":"High","gaps":["Mechanism linking overoxidized PRDX2 to apoptotic threshold unknown","Whether overoxidation gain-of-function (e.g., chaperone) contributes was not tested"]},{"year":2004,"claim":"Two discoveries resolved how PRDX2 overoxidation is reversed and what happens in its complete absence in vivo: sestrin 2 was identified as the ATP-dependent sulfinyl reductase that regenerates overoxidized PRDX2, while PRDX2-knockout mice revealed a non-redundant role in thymocyte apoptosis and immune homeostasis through ROS control.","evidence":"In vitro reconstitution with purified sestrin 2; PrxII-knockout mouse with FACS and apoptosis analysis","pmids":["15105503","15259009"],"confidence":"High","gaps":["Whether other sestrins contribute in specific tissues was not addressed","Molecular targets of elevated ROS in PRDX2-null thymocytes unidentified"]},{"year":2005,"claim":"Demonstration that PRDX2 is recruited to PDGF receptor and locally eliminates H₂O₂ to suppress receptor signaling established the first paradigm for PRDX2 as a spatially targeted signaling modulator rather than merely a bulk antioxidant.","evidence":"Co-immunoprecipitation of PDGFR-PRDX2, Prdx2-knockout mouse, inactive-mutant control, murine restenosis model","pmids":["15902258"],"confidence":"High","gaps":["How PRDX2 is recruited to PDGFR (adaptor, direct binding domain) uncharacterized","Generalizability to other RTKs not tested"]},{"year":2006,"claim":"Showing that erythrocyte PRDX2 operates as a stoichiometric H₂O₂ scavenger—exquisitely sensitive to oxidation yet resistant to overoxidation due to limiting thioredoxin reductase—resolved the paradox of how an abundant peroxiredoxin protects cells with negligible catalytic turnover.","evidence":"Non-reducing SDS-PAGE dimerization assay, thioredoxin reductase activity measurement in erythrocyte hemolysates","pmids":["17105810"],"confidence":"High","gaps":["Quantitative contribution of stoichiometric scavenging vs. residual enzymatic turnover not fully delineated"]},{"year":2007,"claim":"Two advances defined PRDX2 substrate selectivity and a disease-relevant inactivation mechanism: kinetic measurements established ~10⁷ M⁻¹ s⁻¹ reactivity highly selective for H₂O₂ over other oxidants, while Cdk5-mediated Thr89 phosphorylation was identified as an inactivating modification that promotes dopaminergic neuron death, with elevated pThr89-PRDX2 detected in Parkinson's disease brain tissue.","evidence":"Competition kinetics with HRP; Co-IP of Prx2-Cdk5/p35, T89A/T89E mutagenesis, MPP+/MPTP model, p35-KO neurons, postmortem PD brain immunostaining","pmids":["17329258","17610816"],"confidence":"High","gaps":["Whether Thr89 phosphorylation occurs in non-neuronal contexts unknown","Crystal structure of phospho-PRDX2 not determined"]},{"year":2008,"claim":"Identification of HDAC6 as the specific deacetylase of PRDX2 revealed acetylation as a positive regulatory PTM that enhances peroxidase activity and resistance to overoxidation, adding a second layer of post-translational control beyond phosphorylation.","evidence":"HDAC6-knockout/inhibition, in vitro deacetylase assay, H₂O₂ reduction and hyperoxidation assays","pmids":["18606987"],"confidence":"High","gaps":["Identity of the acetyltransferase(s) responsible for PRDX2 acetylation unknown","Specific acetylated lysine residues and their individual contributions unresolved"]},{"year":2009,"claim":"Extension of the calpain→Cdk5→PRDX2 phosphorylation axis to ischemic stroke models demonstrated that cytoplasmic Cdk5-mediated PRDX2 inactivation is a general mechanism of oxidative neuronal death, not restricted to dopaminergic toxins.","evidence":"Focal and global ischemia mouse models with compartment-specific dominant-negative Cdk5 and Prx2 manipulation","pmids":["19812325"],"confidence":"High","gaps":["Whether other cytoplasmic Cdk5 substrates contribute to ischemic death alongside PRDX2 not dissected"]},{"year":2011,"claim":"Native proteomics revealed that erythrocyte PRDX2 exists in multiple oligomeric states including a functional 440 kDa hetero-complex with catalase, and that oxidative stress triggers membrane translocation of oxidized PRDX2, suggesting compartmentalized antioxidant networks.","evidence":"BN-PAGE, 2D-DIGE, size-exclusion chromatography, MS identification, peroxidase activity of isolated complexes","pmids":["21354257"],"confidence":"High","gaps":["Functional significance of membrane-translocated PRDX2 not established","Whether the catalase-PRDX2 complex exists in nucleated cells unknown"]},{"year":2014,"claim":"Two studies established PRDX2 as a bona fide redox signal transducer: it oxidizes STAT3 via disulfide relay to attenuate STAT3 transcriptional activity, and it is released as glutathionylated PRDX2 from LPS-stimulated macrophages to trigger TNF-α-mediated inflammation, demonstrating both intracellular and extracellular signaling functions.","evidence":"In vitro redox reconstitution of PRDX2-STAT3 relay with reporter assays; MS identification of glutathionylated PRDX2 in macrophage secretome with TNF-α ELISA","pmids":["25402766","25097261"],"confidence":"High","gaps":["Full set of PRDX2 relay partners beyond STAT3 not mapped","Receptor mediating extracellular glutathionylated PRDX2 signaling not identified"]},{"year":2015,"claim":"Biophysical analysis showed that peroxynitrite-mediated tyrosine nitration shifts reduced PRDX2 into a conformation resembling the disulfide-oxidized form, mechanistically explaining the observed increase in peroxidase activity upon nitration.","evidence":"Analytical ultracentrifugation, CD, steady-state and time-resolved fluorescence of recombinant PRDX2","pmids":["26612102"],"confidence":"High","gaps":["In vivo relevance of nitrated PRDX2 not demonstrated","Specific nitrated tyrosine residues responsible not individually mutated"]},{"year":2018,"claim":"The kinetic basis for PRDX2's superior signaling capacity was established: its intramolecular disulfide forms 55-fold slower than PRDX1's (0.2 vs. 11 s⁻¹), prolonging the sulfenic acid intermediate available for mixed-disulfide transfer to signaling partners.","evidence":"In vitro kinetics with recombinant PRDX1 and PRDX2, intrinsic fluorescence monitoring","pmids":["30284335"],"confidence":"High","gaps":["Structural basis for the slow resolution rate not determined","Whether the prolonged sulfenic acid reacts with specific partners preferentially not tested"]},{"year":2019,"claim":"REV7 was identified as a partner that recruits PRDX2 to nuclear DNA double-strand break foci, revealing a previously unrecognized nuclear antioxidant function at DNA damage sites that contributes to radioresistance.","evidence":"Proteomics of REV7 interactors, Co-IP, immunofluorescence co-localization, REV7 knockdown with γH2AX and ROS assays","pmids":["30657231"],"confidence":"Medium","gaps":["Direct biochemical reconstitution of REV7-PRDX2 interaction not performed","Whether PRDX2 peroxidase activity vs. chaperone activity is relevant at DSBs unknown","Single lab finding not independently confirmed"]},{"year":2020,"claim":"Multiple studies positioned PRDX2 as a signaling node upstream of MAPK pathways: PRDX2 depletion activates p38 MAPK/FOXO to arrest cell cycle and induce autophagy in colorectal cancer, while PRDX2 overexpression suppresses p38/JNK/ERK in vascular smooth muscle cells, establishing MAPK suppression as a conserved downstream consequence of PRDX2 activity.","evidence":"shRNA knockdown with p38 activator rescue and xenograft model; overexpression/siRNA with MAPK inhibitor epistasis in VSMCs","pmids":["32692719","33791345"],"confidence":"Medium","gaps":["Whether PRDX2 acts on MAPKs through direct H₂O₂ scavenging or specific protein interactions not distinguished","Cell-type specificity of MAPK branch preference unexplored"]},{"year":2022,"claim":"PRDX2 was placed upstream of Akt/mTOR signaling: oxiconazole-induced PRDX2 depletion inactivated Akt/mTOR and caused autophagic arrest, while PRDX2 overexpression rescued, establishing PRDX2 as a regulator of autophagy flux via the Akt/mTOR axis.","evidence":"Drug-induced PRDX2 depletion with overexpression rescue, autophagy flux assays, Akt/mTOR pathway analysis in CRC xenograft","pmids":["35813474"],"confidence":"Medium","gaps":["Direct molecular link between PRDX2 and Akt activation not identified","Whether this involves redox modification of Akt pathway phosphatases unknown"]},{"year":null,"claim":"Key unresolved questions include the full repertoire of PRDX2 sulfenic-acid relay partners beyond STAT3, the receptor mediating extracellular glutathionylated PRDX2 inflammatory signaling, the structural basis for PRDX2's slow disulfide resolution that favors signal transmission, and how PRDX2 is spatially recruited to specific signaling complexes (PDGFR, DSB foci).","evidence":"","pmids":[],"confidence":"High","gaps":["Comprehensive mapping of PRDX2 sulfenic acid interactome not performed","No structural model of the PRDX2-STAT3 relay complex","Mechanism of PRDX2 recruitment to PDGFR and DNA damage foci undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016209","term_label":"antioxidant activity","supporting_discovery_ids":[0,1,6,7,12,16]},{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[17]},{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,7,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,12,13]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,6,10,11]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[11]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[13]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[19]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,12,21,25]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[1,6,7,14,16]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,13,22]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,2,8,23]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[21,26]}],"complexes":["PRDX2 decameric toroid (five homodimers)","PRDX2-catalase hetero-oligomeric complex (erythrocyte)"],"partners":["STAT3","PDGFRB","CDK5","HDAC6","SESN2","MAD2L2","DNMT3A","CAT"],"other_free_text":[]},"mechanistic_narrative":"PRDX2 is a 2-Cys peroxiredoxin that scavenges hydrogen peroxide with exceptional selectivity and reactivity (~10⁷ M⁻¹ s⁻¹) and transduces H₂O₂ signals to downstream effectors through its unusually long-lived sulfenic acid intermediate [PMID:10873855, PMID:17329258, PMID:30284335]. Assembled as a decameric toroid of five homodimers, PRDX2 is recruited to activated PDGF receptor to locally suppress H₂O₂-dependent signaling, and oxidizes STAT3 via a disulfide relay that attenuates STAT3 transcriptional activity, while its glutathionylated form is released from macrophages as an inflammatory danger signal triggering TNF-α production [PMID:15902258, PMID:25402766, PMID:25097261]. PRDX2 activity is regulated by Cdk5-mediated Thr89 phosphorylation (inactivating, contributing to neuronal death in Parkinson's disease and ischemia), HDAC6-dependent deacetylation (modulating activity and overoxidation resistance), and peroxynitrite-mediated tyrosine nitration (activating), while overoxidized enzyme is regenerated by the p53-regulated sulfinyl reductase sestrin 2 [PMID:17610816, PMID:18606987, PMID:26612102, PMID:15105503]. In erythrocytes, PRDX2 operates as a stoichiometric H₂O₂ scavenger that forms a native complex with catalase, and its oxidized form exhibits molecular chaperone activity that prevents protein aggregation [PMID:17105810, PMID:21354257, PMID:30605715]."},"prefetch_data":{"uniprot":{"accession":"P32119","full_name":"Peroxiredoxin-2","aliases":["Natural killer cell-enhancing factor B","NKEF-B","PRP","Thiol-specific antioxidant protein","TSA","Thioredoxin peroxidase 1","Thioredoxin-dependent peroxide reductase 1","Thioredoxin-dependent peroxiredoxin 2"],"length_aa":198,"mass_kda":21.9,"function":"Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P32119/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRDX2","classification":"Not Classified","n_dependent_lines":96,"n_total_lines":1208,"dependency_fraction":0.07947019867549669},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"ACTR2","stoichiometry":0.2},{"gene":"COPB2","stoichiometry":0.2},{"gene":"COPE","stoichiometry":0.2},{"gene":"SAR1B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PRDX2","total_profiled":1310},"omim":[{"mim_id":"617583","title":"SULFIREDOXIN 1; SRXN1","url":"https://www.omim.org/entry/617583"},{"mim_id":"603887","title":"TIMELESS CIRCADIAN REGULATOR; TIMELESS","url":"https://www.omim.org/entry/603887"},{"mim_id":"600538","title":"PEROXIREDOXIN 2; PRDX2","url":"https://www.omim.org/entry/600538"},{"mim_id":"300927","title":"PEROXIREDOXIN 4; PRDX4","url":"https://www.omim.org/entry/300927"},{"mim_id":"191170","title":"TUMOR PROTEIN p53; TP53","url":"https://www.omim.org/entry/191170"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PRDX2"},"hgnc":{"alias_symbol":["PRP","NKEFB","TSA","PRXII","PRX2","MGC4104"],"prev_symbol":["TDPX1"]},"alphafold":{"accession":"P32119","domains":[{"cath_id":"3.40.30.10","chopping":"9-150","consensus_level":"high","plddt":98.3157,"start":9,"end":150},{"cath_id":"-","chopping":"151-198","consensus_level":"medium","plddt":98.3056,"start":151,"end":198}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P32119","model_url":"https://alphafold.ebi.ac.uk/files/AF-P32119-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P32119-F1-predicted_aligned_error_v6.png","plddt_mean":97.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRDX2","jax_strain_url":"https://www.jax.org/strain/search?query=PRDX2"},"sequence":{"accession":"P32119","fasta_url":"https://rest.uniprot.org/uniprotkb/P32119.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P32119/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P32119"}},"corpus_meta":[{"pmid":"8635458","id":"PMC_8635458","title":"Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie.","date":"1996","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8635458","citation_count":746,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12386337","id":"PMC_12386337","title":"Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12386337","citation_count":383,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17610816","id":"PMC_17610816","title":"Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease.","date":"2007","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/17610816","citation_count":216,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9729491","id":"PMC_9729491","title":"Prx1 and Prx2 in skeletogenesis: roles in the craniofacial region, inner ear and limbs.","date":"1998","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9729491","citation_count":204,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23648195","id":"PMC_23648195","title":"Growth factor content in PRP and their applicability in medicine.","date":"2012","source":"Journal of biological regulators and homeostatic agents","url":"https://pubmed.ncbi.nlm.nih.gov/23648195","citation_count":184,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9343239","id":"PMC_9343239","title":"RNA aptamers specifically interact with the prion protein PrP.","date":"1997","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9343239","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9263413","id":"PMC_9263413","title":"PrP genetics in sheep and the applications for scrapie and BSE.","date":"1997","source":"Trends in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/9263413","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34384442","id":"PMC_34384442","title":"CircDIDO1 inhibits gastric cancer progression by encoding a novel DIDO1-529aa protein and regulating PRDX2 protein stability.","date":"2021","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34384442","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10903871","id":"PMC_10903871","title":"Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro.","date":"2000","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10903871","citation_count":131,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14522850","id":"PMC_14522850","title":"Trafficking, turnover and membrane topology of PrP.","date":"2003","source":"British medical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/14522850","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14522848","id":"PMC_14522848","title":"PrP knock-out and PrP transgenic mice in prion research.","date":"2003","source":"British medical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/14522848","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30992411","id":"PMC_30992411","title":"Review of concentration yields in commercially available platelet-rich plasma (PRP) systems: a call for PRP standardization.","date":"2019","source":"Regional anesthesia and pain medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30992411","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7479957","id":"PMC_7479957","title":"Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7479957","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31536951","id":"PMC_31536951","title":"PRDX2 protects against oxidative stress induced by H. pylori and promotes resistance to cisplatin in gastric cancer.","date":"2019","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/31536951","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1618776","id":"PMC_1618776","title":"Diversity of immunodominant 56-kDa type-specific antigen (TSA) of Rickettsia tsutsugamushi. Sequence and comparative analyses of the genes encoding TSA homologues from four antigenic variants.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1618776","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29720484","id":"PMC_29720484","title":"Ubiquitin-dependent degradation of CDK2 drives the therapeutic differentiation of AML by targeting PRDX2.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/29720484","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23647538","id":"PMC_23647538","title":"The pH-triggered conversion of the PrP(c) to PrP(sc.).","date":"2013","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23647538","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28160167","id":"PMC_28160167","title":"Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.","date":"2017","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/28160167","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34266881","id":"PMC_34266881","title":"Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34266881","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28778873","id":"PMC_28778873","title":"Genetic PrP Prion Diseases.","date":"2018","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/28778873","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10664157","id":"PMC_10664157","title":"Loss of function of the Prx1 and Prx2 homeobox genes alters architecture of the great elastic arteries and ductus arteriosus.","date":"2000","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10664157","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25489498","id":"PMC_25489498","title":"Platlet Rich Plasma (PRP) Improves Fat Grafting Outcomes.","date":"2013","source":"World journal of plastic surgery","url":"https://pubmed.ncbi.nlm.nih.gov/25489498","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22396643","id":"PMC_22396643","title":"PK-sensitive PrP is infectious and shares basic structural features with PK-resistant PrP.","date":"2012","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22396643","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25615858","id":"PMC_25615858","title":"Protein-ligand interactions investigated by thermal shift assays (TSA) and dual polarization interferometry (DPI).","date":"2015","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/25615858","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22745483","id":"PMC_22745483","title":"The N-terminal, polybasic region of PrP(C) dictates the efficiency of prion propagation by binding to PrP(Sc).","date":"2012","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22745483","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19812325","id":"PMC_19812325","title":"Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19812325","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32609799","id":"PMC_32609799","title":"Tyramide signal amplification mass spectrometry (TSA-MS) ratio identifies nuclear speckle proteins.","date":"2020","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32609799","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29414853","id":"PMC_29414853","title":"The Structure of PrPSc Prions.","date":"2018","source":"Pathogens (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/29414853","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15483265","id":"PMC_15483265","title":"Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation.","date":"2004","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/15483265","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31185618","id":"PMC_31185618","title":"Role of Cytosolic 2-Cys Prx1 and Prx2 in Redox Signaling.","date":"2019","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31185618","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12514748","id":"PMC_12514748","title":"Genomic characterization of the human prion protein (PrP) gene locus.","date":"2002","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/12514748","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18691383","id":"PMC_18691383","title":"Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18691383","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11373278","id":"PMC_11373278","title":"The identification of Prx1 transcription regulatory domains provides a mechanism for unequal compensation by the Prx1 and Prx2 loci.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11373278","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18258168","id":"PMC_18258168","title":"Progress and limits of PrP gene selection policy.","date":"2008","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/18258168","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24509692","id":"PMC_24509692","title":"The GPI-anchoring of PrP: implications in sorting and pathogenesis.","date":"2014","source":"Prion","url":"https://pubmed.ncbi.nlm.nih.gov/24509692","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14522849","id":"PMC_14522849","title":"Putative functions of PrP(C).","date":"2003","source":"British medical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/14522849","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15670743","id":"PMC_15670743","title":"PrP cooperates with STI1 to regulate SOD activity in PrP-deficient neuronal cell line.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15670743","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12943237","id":"PMC_12943237","title":"Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, is under-expressed in Down syndrome fetal brains.","date":"2003","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/12943237","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33632047","id":"PMC_33632047","title":"An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects.","date":"2021","source":"Systems biology in reproductive medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33632047","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31042308","id":"PMC_31042308","title":"Platelet-Rich Plasma (PRP) From Older Males With Knee Osteoarthritis Depresses Chondrocyte Metabolism and Upregulates Inflammation.","date":"2019","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/31042308","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15259009","id":"PMC_15259009","title":"Reactive oxygen species induced by the deletion of peroxiredoxin II (PrxII) increases the number of thymocytes resulting in the enlargement of PrxII-null thymus.","date":"2004","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15259009","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30284335","id":"PMC_30284335","title":"Differential parameters between cytosolic 2-Cys peroxiredoxins, PRDX1 and PRDX2.","date":"2018","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/30284335","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33268762","id":"PMC_33268762","title":"Peroxiredoxin2 (Prdx2) Reduces Oxidative Stress and Apoptosis of Myocardial Cells Induced by Acute Myocardial Infarction by Inhibiting the TLR4/Nuclear Factor kappa B (NF-κB) Signaling Pathway.","date":"2020","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/33268762","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21354257","id":"PMC_21354257","title":"Oxidative stress-dependent oligomeric status of erythrocyte peroxiredoxin II (PrxII) during storage under standard blood banking conditions.","date":"2011","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/21354257","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28432271","id":"PMC_28432271","title":"Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway.","date":"2017","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/28432271","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11244566","id":"PMC_11244566","title":"Identification of domains mediating transcription activation, repression, and inhibition in the paired-related homeobox protein, Prx2 (S8).","date":"2001","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11244566","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30605715","id":"PMC_30605715","title":"Protective and adaptogenic role of peroxiredoxin 2 (Prx2) in neutralization of oxidative stress induced by ionizing radiation.","date":"2018","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30605715","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12482851","id":"PMC_12482851","title":"The PrP-like protein Doppel binds copper.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12482851","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15354865","id":"PMC_15354865","title":"The role of PrP in health and disease.","date":"2004","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15354865","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30657231","id":"PMC_30657231","title":"REV7 confers radioresistance of esophagus squamous cell carcinoma by recruiting PRDX2.","date":"2019","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/30657231","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31583788","id":"PMC_31583788","title":"Transition of the prion protein from a structured cellular form (PrPC ) to the infectious scrapie agent (PrPSc ).","date":"2019","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/31583788","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18535006","id":"PMC_18535006","title":"TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels.","date":"2008","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/18535006","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20339552","id":"PMC_20339552","title":"A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20339552","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26553935","id":"PMC_26553935","title":"Traditional serrated adenoma (TSA): morphological questions, queries and quandaries.","date":"2015","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26553935","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16562966","id":"PMC_16562966","title":"Three in one: TSA, TSA', and SA units in one crystal structure of a yttrium(III) complex with a monophosphinated H4dota analogue.","date":"2006","source":"Inorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16562966","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21728138","id":"PMC_21728138","title":"The PrP-like proteins Shadoo and Doppel.","date":"2011","source":"Topics in current chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21728138","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19777594","id":"PMC_19777594","title":"Prx1 and Prx2 cooperatively regulate the morphogenesis of the medial region of the mandibular process.","date":"2009","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/19777594","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19032984","id":"PMC_19032984","title":"Structure, organization and expression of common carp (Cyprinus carpio L.) NKEF-B gene.","date":"2008","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19032984","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28578703","id":"PMC_28578703","title":"Effects of platelet rich plasma (PRP) on human gingival fibroblast, osteoblast and periodontal ligament cell behaviour.","date":"2017","source":"BMC oral health","url":"https://pubmed.ncbi.nlm.nih.gov/28578703","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24721836","id":"PMC_24721836","title":"PrP overdrive: does inhibition of α-cleavage contribute to PrP(C) toxicity and prion disease?","date":"2014","source":"Prion","url":"https://pubmed.ncbi.nlm.nih.gov/24721836","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38219498","id":"PMC_38219498","title":"Implications and progression of peroxiredoxin 2 (PRDX2) in various human diseases.","date":"2024","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/38219498","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30245403","id":"PMC_30245403","title":"Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.","date":"2018","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30245403","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28096244","id":"PMC_28096244","title":"Experimental Models of Inherited PrP Prion Diseases.","date":"2017","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28096244","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19925901","id":"PMC_19925901","title":"Design and delivery of a cryptic PrP(C) epitope for induction of PrP(Sc)-specific antibody responses.","date":"2009","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/19925901","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25682994","id":"PMC_25682994","title":"Functional and structural changes in plant mitochondrial PrxII F caused by NO.","date":"2015","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/25682994","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7535178","id":"PMC_7535178","title":"Preparation and characterization of antibodies against mouse prion protein (PrP) peptides.","date":"1995","source":"Clinical and diagnostic laboratory immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7535178","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31968660","id":"PMC_31968660","title":"STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31968660","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9031631","id":"PMC_9031631","title":"Characterization of a prion protein (PrP) gene from rabbit; a species with apparent resistance to infection by prions.","date":"1997","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9031631","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32692719","id":"PMC_32692719","title":"PRDX2 removal inhibits the cell cycle and autophagy in colorectal cancer cells.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32692719","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28765537","id":"PMC_28765537","title":"PRDX2 in Myocyte Hypertrophy and Survival is Mediated by TLR4 in Acute Infarcted Myocardium.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28765537","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7622046","id":"PMC_7622046","title":"A candidate marsupial PrP gene reveals two domains conserved in mammalian PrP proteins.","date":"1995","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/7622046","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32130676","id":"PMC_32130676","title":"PRDX2 plays an oncogenic role in esophageal squamous cell carcinoma via Wnt/β-catenin and AKT pathways.","date":"2020","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/32130676","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37446194","id":"PMC_37446194","title":"EGCG, GCG, TFDG, or TSA Inhibiting Melanin Synthesis by Downregulating MC1R Expression.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37446194","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33017884","id":"PMC_33017884","title":"Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis.","date":"2020","source":"Cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/33017884","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34529657","id":"PMC_34529657","title":"Platelet HMGB1 in Platelet-Rich Plasma (PRP) promotes tendon wound healing.","date":"2021","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/34529657","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31924264","id":"PMC_31924264","title":"Goats naturally devoid of PrPC are resistant to scrapie.","date":"2020","source":"Veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/31924264","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25339198","id":"PMC_25339198","title":"Expression pattern of the PRDX2, RAB1A, RAB1B, RAB5A and RAB25 genes in normal and cancer cervical tissues.","date":"2014","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25339198","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12415222","id":"PMC_12415222","title":"Do ambulatory-use Platelet-Rich Plasma (PRP) concentrates present risks?","date":"2002","source":"Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal","url":"https://pubmed.ncbi.nlm.nih.gov/12415222","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24039764","id":"PMC_24039764","title":"The ZIP5 ectodomain co-localizes with PrP and may acquire a PrP-like fold that assembles into a dimer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24039764","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30521599","id":"PMC_30521599","title":"Global analysis of erythroid cells redox status reveals the involvement of Prdx1 and Prdx2 in the severity of beta thalassemia.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30521599","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22437735","id":"PMC_22437735","title":"Unraveling the neuroprotective mechanisms of PrP (C) in excitotoxicity.","date":"2012","source":"Prion","url":"https://pubmed.ncbi.nlm.nih.gov/22437735","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35813474","id":"PMC_35813474","title":"Repurposing Oxiconazole against Colorectal Cancer via PRDX2-mediated Autophagy Arrest.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35813474","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27847358","id":"PMC_27847358","title":"PrP Knockout Cells Expressing Transmembrane PrP Resist Prion Infection.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/27847358","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17258625","id":"PMC_17258625","title":"Prion protein (PrP) in human teeth: an unprecedented pointer to PrP's function.","date":"2007","source":"Journal of endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/17258625","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30914754","id":"PMC_30914754","title":"PMCA-replicated PrPD in urine of vCJD patients maintains infectivity and strain characteristics of brain PrPD: Transmission study.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30914754","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32258495","id":"PMC_32258495","title":"What is the potential use of platelet-rich-plasma (PRP) in cancer treatment? A mini review.","date":"2020","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/32258495","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16455503","id":"PMC_16455503","title":"[Histone-deacetylases inhibitors: from TSA to SAHA].","date":"2006","source":"Bulletin du cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16455503","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30896295","id":"PMC_30896295","title":"Autologous Platelet-Rich Plasma (CuteCell PRP) Safely Boosts In Vitro Human Fibroblast Expansion.","date":"2019","source":"Tissue engineering. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/30896295","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37523836","id":"PMC_37523836","title":"Dihydromyricetin confers cerebroprotection against subarachnoid hemorrhage via the Nrf2-dependent Prx2 signaling cascade.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37523836","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28989689","id":"PMC_28989689","title":"Semisynthetic prion protein (PrP) variants carrying glycan mimics at position 181 and 197 do not form fibrils.","date":"2017","source":"Chemical science","url":"https://pubmed.ncbi.nlm.nih.gov/28989689","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23922744","id":"PMC_23922744","title":"PrP(ST), a soluble, protease resistant and truncated PrP form features in the pathogenesis of a genetic prion disease.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23922744","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25364762","id":"PMC_25364762","title":"Regulation of PrP(C) signaling and processing by dimerization.","date":"2014","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/25364762","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31807984","id":"PMC_31807984","title":"Prdx2 Upregulation Promotes the Growth and Survival of Gastric Cancer Cells.","date":"2019","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/31807984","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33791345","id":"PMC_33791345","title":"PRDX2 Protects Against Atherosclerosis by Regulating the Phenotype and Function of the Vascular Smooth Muscle Cell.","date":"2021","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33791345","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41226837","id":"PMC_41226837","title":"Platelet-Rich Plasma (PRP): Molecular Mechanisms, Actions and Clinical Applications in Human Body.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41226837","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18068119","id":"PMC_18068119","title":"A monoclonal antibody (1D12) defines novel distribution patterns of prion protein (PrP) as granules in nucleus.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18068119","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26612102","id":"PMC_26612102","title":"Structural changes upon peroxynitrite-mediated nitration of peroxiredoxin 2; nitrated Prx2 resembles its disulfide-oxidized form.","date":"2015","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/26612102","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31498962","id":"PMC_31498962","title":"Effects of PRP and LyPRP on osteogenic differentiation of MSCs.","date":"2019","source":"Journal of biomedical materials research. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/31498962","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11748565","id":"PMC_11748565","title":"Comparative analysis of Prx1 and Prx2 expression in mice provides evidence for incomplete compensation.","date":"2002","source":"The Anatomical record","url":"https://pubmed.ncbi.nlm.nih.gov/11748565","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26536866","id":"PMC_26536866","title":"Mammalian prion protein (PrP) forms conformationally different amyloid intracellular aggregates in bacteria.","date":"2015","source":"Microbial cell factories","url":"https://pubmed.ncbi.nlm.nih.gov/26536866","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29507755","id":"PMC_29507755","title":"VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/29507755","citation_count":829,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15105503","id":"PMC_15105503","title":"Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD.","date":"2004","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15105503","citation_count":625,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28302793","id":"PMC_28302793","title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.","date":"2017","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28302793","citation_count":533,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25402766","id":"PMC_25402766","title":"Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling.","date":"2014","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/25402766","citation_count":495,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10751410","id":"PMC_10751410","title":"Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10751410","citation_count":385,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26414014","id":"PMC_26414014","title":"Proteome-wide profiling of protein assemblies by cross-linking mass spectrometry.","date":"2015","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/26414014","citation_count":370,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11904290","id":"PMC_11904290","title":"Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11904290","citation_count":327,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15902258","id":"PMC_15902258","title":"Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/15902258","citation_count":325,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21145461","id":"PMC_21145461","title":"Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21145461","citation_count":318,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17329258","id":"PMC_17329258","title":"The high reactivity of peroxiredoxin 2 with H(2)O(2) is not reflected in its reaction with other oxidants and thiol reagents.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17329258","citation_count":311,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18606987","id":"PMC_18606987","title":"HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18606987","citation_count":282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25097261","id":"PMC_25097261","title":"Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25097261","citation_count":282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22863883","id":"PMC_22863883","title":"A high-throughput approach for measuring temporal changes in the interactome.","date":"2012","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/22863883","citation_count":273,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10873855","id":"PMC_10873855","title":"Crystal structure of decameric 2-Cys peroxiredoxin from human erythrocytes at 1.7 A resolution.","date":"2000","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/10873855","citation_count":268,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19199708","id":"PMC_19199708","title":"Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT).","date":"2009","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/19199708","citation_count":237,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22902630","id":"PMC_22902630","title":"Peroxiredoxin 1 functions as a signal peroxidase to receive, transduce, and transmit peroxide signals in mammalian cells.","date":"2012","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22902630","citation_count":236,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12650976","id":"PMC_12650976","title":"Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders.","date":"2003","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/12650976","citation_count":232,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17105810","id":"PMC_17105810","title":"Peroxiredoxin 2 functions as a noncatalytic scavenger of low-level hydrogen peroxide in the erythrocyte.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17105810","citation_count":232,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20458337","id":"PMC_20458337","title":"MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis.","date":"2010","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20458337","citation_count":221,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28524877","id":"PMC_28524877","title":"Optimized fragmentation schemes and data analysis strategies for proteome-wide cross-link identification.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28524877","citation_count":221,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27173435","id":"PMC_27173435","title":"An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27173435","citation_count":211,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26618866","id":"PMC_26618866","title":"∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26618866","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11986303","id":"PMC_11986303","title":"Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11986303","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48627,"output_tokens":4568,"usd":0.107201},"stage2":{"model":"claude-opus-4-6","input_tokens":8046,"output_tokens":3657,"usd":0.197483},"total_usd":0.716221,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":61788,"output_tokens":9033,"usd":0.16043},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11541,"output_tokens":4388,"usd":0.251107}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"Cdk5/p35 phosphorylates PRDX2 at threonine 89 (T89) in neurons treated with MPP+/MPTP in a calpain/Cdk5/p35-dependent manner, and this phosphorylation reduces PRDX2 peroxidase activity. Expression of the phosphorylation-resistant mutant PRDX2T89A (but not the phosphomimetic PRDX2T89E) protects dopaminergic neurons from mitochondrial insult, establishing a mechanistic pathway whereby mitochondrial toxin → calpain → Cdk5 activation → reduced PRDX2 activity → increased ROS → neuronal death.\",\n      \"method\": \"Biochemical phosphorylation assays, site-directed mutagenesis (T89A and T89E), peroxidase activity assays, neuronal protection assays in cultured and adult neurons, in vivo MPTP mouse model, postmortem Parkinson's disease tissue analysis\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including mutagenesis, in vitro activity assays, in vivo models, and human tissue validation in a single study\",\n      \"pmids\": [\"17610816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Cytoplasmic Cdk5 phosphorylates and inactivates PRDX2 in ischemia models in vivo. Expression of cytoplasm-restricted dominant-negative Cdk5 is neuroprotective, and PRDX2 is established as a critical cytoplasmic substrate of Cdk5 in both focal and global stroke models.\",\n      \"method\": \"In vivo focal and global ischemia models, compartment-specific dominant-negative Cdk5 constructs, phosphorylation assays, neuronal death quantification\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo epistasis with compartment-specific constructs, replicated in two stroke models, corroborating the prior Cdk5-PRDX2 mechanism\",\n      \"pmids\": [\"19812325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CDK2 directly maintains PRDX2 activity in AML cells to block myeloid differentiation. CDK2 depletion leads to loss of PRDX2 activity, increased ROS, and granulocytic differentiation, placing CDK2 upstream of PRDX2 in a differentiation-blocking axis.\",\n      \"method\": \"Yeast two-hybrid, functional analyses, CDK2 knockdown/inhibition in AML cell lines and primary patient samples, xenograft mouse models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — yeast 2-hybrid plus functional cell and in vivo validation, single lab\",\n      \"pmids\": [\"29720484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CircDIDO1 specifically binds to PRDX2 protein and promotes RBX1-mediated ubiquitination and proteasomal degradation of PRDX2, leading to inactivation of PRDX2-dependent downstream signaling pathways in gastric cancer cells.\",\n      \"method\": \"Tagged RNA affinity purification, mass spectrometry, co-immunoprecipitation, Western blot, mouse tumor models\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP and MS identification of PRDX2 as circRNA binding partner, functional validation with ubiquitination assay\",\n      \"pmids\": [\"34384442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"REV7 interacts with PRDX2 and recruits it to the nucleus, particularly to DNA double-strand break sites after irradiation. REV7 knockdown disrupts nuclear PRDX2 localization and increases oxidative stress and unrepaired DSBs, establishing a REV7-PRDX2 complex in radioresistance.\",\n      \"method\": \"Proteomic analysis of REV7-interacting proteins, co-immunoprecipitation, immunofluorescence, REV7 knockdown with phenotypic readouts (ROS, DSBs, colony formation)\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP validated by immunofluorescence co-localization and functional consequence of KD on nuclear PRDX2\",\n      \"pmids\": [\"30657231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DNMT3A-R882H/C mutations upregulate PRDX2 expression via hypomethylation of the PRDX2 locus, reducing ROS accumulation and thereby impairing apoptosis in myeloid leukemia cells. Both DNMT3A-WT and R882H/C mutants interact with PRDX2 protein.\",\n      \"method\": \"Gene expression profiling, DNA methylation assay, co-immunoprecipitation, ROS measurement, PRDX2 knockdown with apoptosis/proliferation assays\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP-level methylation, Co-IP, functional KD), single lab\",\n      \"pmids\": [\"30245403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"H. pylori infection induces NF-κB activation which transcriptionally upregulates PRDX2 (NF-κB-p65 binding site confirmed on the PRDX2 promoter by luciferase reporter and ChIP assays). PRDX2 knockdown increases ROS, oxidative DNA damage, and double-strand breaks in response to H. pylori.\",\n      \"method\": \"Luciferase reporter assay, ChIP assay, PRDX2 knockdown, ROS measurement (H2DCFDA), 8-oxoguanine and γ-H2AX assays, in vitro and in vivo H. pylori models\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and luciferase confirm NF-κB regulation of PRDX2 promoter, combined with functional KD and in vivo models\",\n      \"pmids\": [\"31536951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PRDX2 peroxidatic cysteine (CP) reacts with H2O2 at a rate ~10-fold faster than with peroxynitrite; the disulfide formation rate (resolution step) for PRDX2 is 0.2 s⁻¹, ~55-fold slower than PRDX1 (11 s⁻¹). This kinetic difference prolongs the PRDX2 sulfenic acid lifetime, enabling it to react with other protein thiols to form mixed disulfides and relay redox signals, rather than completing the intramolecular catalytic cycle.\",\n      \"method\": \"In vitro kinetics of recombinant human PRDX2 using intrinsic fluorescence, comparison with PRDX1 at pH 7.4 with H2O2 and peroxynitrite\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with recombinant protein, quantitative kinetic characterization of catalytic mechanism\",\n      \"pmids\": [\"30284335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Peroxynitrite-mediated nitration of PRDX2 on non-catalytic tyrosines causes structural changes (reduced nitrated Prx2 resembles the disulfide-oxidized form), which facilitates disulfide formation and explains the kinetically observed increase in peroxidase activity and resistance to overoxidation upon nitration.\",\n      \"method\": \"Analytical ultracentrifugation, UV absorption, circular dichroism, steady-state and time-resolved fluorescence of recombinant human Prx2 after GSNO/peroxynitrite treatment\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple biophysical methods on recombinant protein defining structural basis for PTM-dependent activity change\",\n      \"pmids\": [\"26612102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Deletion of the PRDX2 (PrxII) gene in mice increases ROS levels in thymocytes, leading to thymus enlargement due to reduced apoptosis and increased thymocyte number. PrxII-null thymocytes show lower hypodiploid cell formation and resist apoptosis induced by food restriction or dexamethasone, demonstrating PRDX2's role in ROS-dependent regulation of thymocyte development and selection.\",\n      \"method\": \"PrxII knockout mice, ROS measurement in thymocytes, flow cytometry (SP/DP ratio, apoptosis), dexamethasone and food restriction challenges, T cell proliferation assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with multiple defined cellular phenotypes across different experimental conditions\",\n      \"pmids\": [\"15259009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In human erythrocytes, PRDX2 exists in four oligomeric states in the cytosol: a 440 kDa complex with tetrameric catalase (CAT), and homo-polymeric complexes at 140, 100, and 67 kDa. Upon oxidative stress (28-day storage), the CAT-PRDX2 hetero-oligomeric complex shifts and PRDX2 is recruited to membranes. Peroxidase activity was confirmed for the 440 kDa and 140 kDa oligomers.\",\n      \"method\": \"Proteomics (native gel electrophoresis, mass spectrometry), peroxidase activity assays of isolated oligomers, cytosol/membrane fractionation of fresh and stored erythrocytes\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS identification of complex partners plus functional activity assays on isolated fractions, single lab\",\n      \"pmids\": [\"21354257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PRDX2 functions as an antioxidant enzyme protecting neurons from oxidative damage; stable antisense knockdown of PRDX2 in SH-SY5Y neuroblastoma cells increases sensitivity to oxidative cytotoxic agents and apoptosis under basal conditions, comparable in effect to SOD1 overexpression.\",\n      \"method\": \"Stable antisense transfection of PRDX2 in neuroblastoma cells, cell viability and apoptosis assays under oxidative stress conditions, comparison with SOD1 overexpression\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined cellular phenotypes and mechanistic comparison to SOD1, single lab\",\n      \"pmids\": [\"12943237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRDX2 knockdown in colon cancer cells suppresses PI3K/AKT signaling, sensitizing cells to 5-FU-induced apoptosis. Conversely, PRDX2 overexpression increases p-AKT protein expression, placing PRDX2 upstream of the PI3K/AKT pathway in chemoresistance.\",\n      \"method\": \"shRNA-mediated PRDX2 knockdown, PRDX2 overexpression, Western blot for p-AKT and Bcl-2/Bax, in vitro apoptosis assays, xenograft mouse models, IHC correlation in human tissue\",\n      \"journal\": \"Bioscience reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with defined signaling readouts and in vivo validation\",\n      \"pmids\": [\"28432271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRDX2 removal in colorectal cancer cells activates p38 MAPK signaling, inhibiting cell-cycle progression (S-phase entry) and autophagy flux. A p38 activator partially rescues the effects of PRDX2 knockdown, placing PRDX2 upstream of the p38 MAPK/FOXO pathway.\",\n      \"method\": \"shRNA knockdown, immunostaining, electron microscopy, Western blotting, p38 activator rescue, xenograft mouse model\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via rescue experiment, multiple readouts, in vivo validation, single lab\",\n      \"pmids\": [\"32692719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CASC15 lncRNA binds to PRDX2 protein (RNA pulldown and RIP assays), stabilizes PRDX2 by preventing its proteasomal degradation, and thereby activates PI3K/AKT/c-Myc signaling in intrahepatic cholangiocarcinoma. Overexpressing PRDX2 rescues the signaling block caused by CASC15 knockdown.\",\n      \"method\": \"RNA-pulldown, RNA immunoprecipitation (RIP), proteasome inhibitor rescue experiment, PRDX2 overexpression rescue, PI3K/AKT pathway Western blotting, xenograft models\",\n      \"journal\": \"Cancer research and treatment\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA-protein interaction confirmed by RIP and pulldown, functional rescue confirms PRDX2 as effector, single lab\",\n      \"pmids\": [\"33017884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Oxiconazole downregulates PRDX2 protein levels to increase ROS, which inactivates the Akt/mTOR pathway and inhibits RAB7A-mediated autophagosome-lysosome fusion, causing autophagosome accumulation and CRC cell growth suppression. PRDX2 overexpression rescues this phenotype, positioning PRDX2 as the key mediator of oxiconazole action.\",\n      \"method\": \"PRDX2 overexpression rescue, Akt/mTOR pathway Western blotting, autophagy flux assays, RAB7A functional analysis, CRC cell growth assays\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function rescue places PRDX2 in Akt/mTOR-autophagy pathway, single lab\",\n      \"pmids\": [\"35813474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Exogenous recombinant PRDX2 exhibits chaperone activity in its oxidized form, preventing protein misfolding and aggregation under oxidative stress, in addition to its peroxidase activity. Intravenous administration of recombinant PRDX2 protects against ionizing radiation in vivo.\",\n      \"method\": \"In vitro peroxidase assays, chaperone activity assays, in vivo whole-body X-ray irradiation mouse model, survival analysis, leucopenia/thrombocytopenia quantification, apoptosis and proliferation assays\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — in vitro biochemical characterization of dual peroxidase and chaperone activities, plus in vivo validation, single lab\",\n      \"pmids\": [\"30605715\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRDX2 is a cytosolic typical 2-Cys peroxidase that eliminates H2O2 through a catalytic cysteine cycling between reduced, sulfenic acid, and disulfide states; its unusually slow disulfide formation rate (0.2 s⁻¹) prolongs sulfenic acid lifetime and enables redox relay to partner proteins, its activity is negatively regulated by Cdk5-mediated phosphorylation at T89 (relevant to neurodegeneration and ischemia), its stability is regulated by ubiquitin/proteasome pathways controlled by binding partners including circDIDO1 and CASC15, it interacts with catalase, REV7, and CDK2 to participate in ROS management and DNA damage responses, it adopts chaperone activity in its oxidized form, and its loss-of-function increases ROS to modulate p38 MAPK, PI3K/AKT, and Akt/mTOR signaling pathways governing cell cycle, autophagy, differentiation, and apoptosis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries only from KEEP papers.\n\n**Classification:**\n- Papers 1-13, 15-17, 19-29, 31-32, 34-36, 48-49, 51, 53, 56, 60, 63-64, 66-68, 71, 76, 79, 81, 83-85, 90-92, 96, 100: EXCLUDE (PrP/prion protein, PRP=platelet-rich plasma, TSA=trichostatin A/traditional serrated adenoma/thermal shift assay, Prx1/Prx2 homeobox genes)\n- Paper 4 (Prx1/Prx2 homeobox genes): EXCLUDE - alias collision, these are paired-class homeobox transcription factors, not PRDX2 peroxiredoxin\n- Paper 8 (CircDIDO1/PRDX2): KEEP - describes PRDX2 protein regulation by circRNA\n- Paper 14 (PRDX2 gastric cancer): KEEP\n- Paper 16 (CDK2-PRDX2 AML): KEEP\n- Paper 26 (cdk5/Prx2 ischemia): KEEP - Prx2 = peroxiredoxin 2\n- Paper 30 (Cytosolic 2-Cys Prx1/Prx2 review): KEEP\n- Paper 33: EXCLUDE - Prx1/Prx2 homeobox genes\n- Paper 38 (PRDX2 Down syndrome): KEEP\n- Paper 41 (PrxII-null thymus): KEEP - PrxII = peroxiredoxin 2\n- Paper 42 (PRDX1/PRDX2 kinetics): KEEP\n- Paper 43 (Prdx2 myocardial): KEEP\n- Paper 44 (PrxII erythrocyte oligomers): KEEP\n- Paper 45 (PRDX2 colon cancer/PI3K): KEEP\n- Paper 46: EXCLUDE - Prx2 homeobox transcription factor\n- Paper 47 (Prx2 radioprotection): KEEP\n- Paper 50 (REV7-PRDX2): KEEP\n- Paper 57: EXCLUDE - Prx1/Prx2 homeobox\n- Paper 58 (NKEF-B/carp): EXCLUDE - fish ortholog with limited mechanistic data, also \"NKEF-B\" is more related to PRDX1\n- Paper 61 (PRDX2 review): KEEP\n- Paper 62 (DNMT3A/PRDX2 AML): KEEP\n- Paper 65 (plant PrxII F): EXCLUDE - plant mitochondrial peroxiredoxin, symbol collision\n- Paper 67 (STVNa/Prdx2/cardiac hypertrophy): KEEP\n- Paper 69 (PRDX2 colorectal): KEEP\n- Paper 70 (PRDX2 myocyte/TLR4): KEEP\n- Paper 72 (PRDX2 esophageal): KEEP\n- Paper 74 (CASC15/PRDX2): KEEP\n- Paper 77 (PRDX2 cervical): KEEP - but mostly expression, partial KEEP for splicing data\n- Paper 80 (Prdx1/Prdx2 beta thalassemia): KEEP\n- Paper 82 (PRDX2/autophagy/CRC): KEEP\n- Paper 89 (Nrf2/Prx2 SAH): KEEP\n- Paper 93 (Prdx2 gastric cancer): KEEP\n- Paper 94 (PRDX2 atherosclerosis): KEEP\n- Paper 97 (Prx2 nitration structure): KEEP\n- Paper 99: EXCLUDE - Prx1/Prx2 homeobox proteins\n\n**Additional curated papers:**\n- [7] Sestrins/peroxiredoxin regeneration: KEEP\n- [9] Prx2-STAT3 redox relay: KEEP\n- [14] Proteomics/overoxidation: KEEP\n- [15] PDGF signaling/Prx II: KEEP\n- [17] Prx2 H2O2 reactivity: KEEP\n- [18] HDAC6 deacetylates Prx I/II: KEEP\n- [19] Glutathionylated PRDX2 release: KEEP\n- [21] Crystal structure decameric Prx: KEEP\n- [23] Prdx1 signal peroxidase/ASK1: KEEP (but about Prdx1, not Prdx2 - partial relevance)\n- [24] Peroxiredoxin aberrant expression: KEEP\n- [25] Prx2 erythrocyte scavenger: KEEP\n- [30] PrxI phosphorylation by Cdc2: KEEP (about PrxI, but has PRDX2 context - actually this is specifically about PrxI/PRDX1, not PRDX2, EXCLUDE for PRDX2-specific findings)\n- Others (cDNA collections, proteomics atlases): EXCLUDE for mechanistic findings about PRDX2 specifically\n- [3] VIRMA/m6A: EXCLUDE\n- [8] indisulam/RBM39: EXCLUDE\n- [13] cross-linking MS: EXCLUDE for PRDX2-specific\n- [16] CRL network: EXCLUDE\n- [28] ciliary proteome: EXCLUDE\n- [29] CFTR interactome: EXCLUDE\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Crystal structure of human decameric peroxiredoxin 2 (TPx-B/PRDX2) from erythrocytes was determined at 1.7 Å resolution, revealing a toroid of five head-to-tail homodimers; the active-site Cys51 was oxidized to cysteine sulphinic acid, trapping a stable decamer, and the structure demonstrated that the catalytic cycle requires significant conformational changes including unwinding of the active-site helix and movement of four loops.\",\n      \"method\": \"X-ray crystallography, sedimentation analysis\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional validation by sedimentation\",\n      \"pmids\": [\"10873855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Proteomics analysis of oxidative stress responses showed that the peroxiredoxin active-site cysteine of PRDX2 is overoxidized in vivo to cysteic acid, inactivating the enzyme; the balance of oxidized vs. native PRDX2 plays an active role in resistance or susceptibility to TNF-α-induced apoptosis in Leydig cells.\",\n      \"method\": \"2D gel proteomics, tandem mass spectrometry, cell-based apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — MS-based identification of in vivo modification with functional apoptosis readout\",\n      \"pmids\": [\"11904290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PRDX2 is under-expressed in Down syndrome fetal brains; stable antisense knockdown of PRDX2 in SH-SY5Y neuroblastoma cells increased sensitivity to oxidative stress and apoptosis under basal conditions and after oxidative challenge, at levels comparable to the effect of SOD1 overexpression, demonstrating PRDX2's non-redundant role in neuronal redox defense.\",\n      \"method\": \"Suppression subtractive hybridization, real-time PCR, stable antisense transfection, cell viability and apoptosis assays\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockdown with specific phenotypic readout in single lab\",\n      \"pmids\": [\"12943237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Reactive oxygen species elevated by PRDX2 (PrxII) gene deletion in mice led to enlarged thymus with increased thymocyte numbers; PrxII-null thymocytes showed reduced hypodiploid cell formation and resistance to apoptosis induced by dexamethasone or food restriction, establishing PRDX2 as a regulator of thymocyte survival and maturation through ROS control.\",\n      \"method\": \"PrxII knockout mouse model, FACS analysis of thymocyte subsets, apoptosis assays, proliferation assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knockout with multiple orthogonal phenotypic readouts\",\n      \"pmids\": [\"15259009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Sestrins, whose expression is modulated by p53, are required for regeneration (reduction) of hyperoxidized peroxiredoxins including PRDX2; purified Hi95 (sestrin 2) supports ATP-dependent reduction of overoxidized Prx in vitro, functioning as a cysteine sulfinyl reductase (not a disulfide reductase), thereby reestablishing the antioxidant capacity of PRDX2 after H2O2-mediated overoxidation.\",\n      \"method\": \"In vitro reconstitution with purified proteins, cell-based assays, bioinformatics\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with purified protein, multiple supporting cell-based experiments\",\n      \"pmids\": [\"15105503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PRDX2 (Prx II) is a negative regulator of PDGF receptor signaling: it is recruited to PDGFR upon PDGF stimulation and locally eliminates H2O2 produced in response to PDGF, thereby suppressing protein tyrosine phosphatase inactivation. PRDX2 deficiency results in enhanced H2O2 production, enhanced PDGFR and PLCγ1 activation, increased VSMC proliferation/migration, and PDGF-dependent neointimal thickening in a murine restenosis model.\",\n      \"method\": \"Prdx2 knockout mouse, co-immunoprecipitation (PDGFR-PRDX2 interaction), cell proliferation/migration assays, murine restenosis model, in vitro peroxidase activity (inactive mutant comparison)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP, knockout mouse, inactive mutant control, in vivo model, replicated across multiple assays\",\n      \"pmids\": [\"15902258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PRDX2 functions as a noncatalytic scavenger of low-level hydrogen peroxide in human erythrocytes: it is extremely sensitive to oxidation (dimerization observed at 0.5 µM H2O2), resistant to overoxidation (due to very low thioredoxin reductase activity limiting recycling), and is oxidized by endogenously generated H2O2 from hemoglobin autoxidation, demonstrating its role in erythrocyte defense is stoichiometric rather than enzymatic.\",\n      \"method\": \"H2O2 treatment of erythrocytes, non-reducing SDS-PAGE dimerization assay, thioredoxin reductase activity measurement, hemolysate experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical assays with multiple orthogonal methods, mechanistically rigorous\",\n      \"pmids\": [\"17105810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PRDX2 peroxidase activity is highly selective for H2O2 and organic hydroperoxides (rate constant ~1.3 × 10^7 M^-1 s^-1 for H2O2), but reacts extremely slowly with amino acid chloramines and the alkylating agent iodoacetamide, demonstrating that its tertiary structure facilitates H2O2 reactivity while restricting reactivity with other thiol reagents.\",\n      \"method\": \"Competition kinetics with horseradish peroxidase, non-reducing SDS-PAGE dimerization inhibition assay, multiple oxidant comparisons\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro kinetics with multiple oxidants and controls\",\n      \"pmids\": [\"17329258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PRDX2 (Prx2) is phosphorylated at Thr89 by Cdk5/p35 in neurons treated with MPP+/MPTP; this phosphorylation reduces Prx2 peroxidase activity. Calpain-mediated Cdk5 activation upstream drives this modification. Expression of phosphorylation-resistant Prx2T89A (but not the phosphomimetic Prx2T89E) protects dopaminergic neurons from mitochondrial toxin-induced death, and Prx2 Thr89 phosphorylation is elevated in nigral neurons of Parkinson's disease patients.\",\n      \"method\": \"Co-immunoprecipitation (Prx2-Cdk5/p35), site-directed mutagenesis (T89A, T89E), in vitro peroxidase activity assay, MPP+/MPTP neurotoxicity model, p35 knockout neurons, transgenic overexpression, postmortem human brain immunostaining\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis, in vitro activity assay, Co-IP, KO epistasis, human pathological tissue validation across multiple orthogonal methods\",\n      \"pmids\": [\"17610816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HDAC6 is a specific deacetylase of PRDX2 (and PRDX1); acetylation of PRDX2 (accumulating when HDAC6 is inactive) increases its H2O2-reducing activity, its resistance to superoxidation, and its resistance to transition to high-molecular-mass complexes, identifying acetylation as a positive regulatory PTM for PRDX2 enzymatic function.\",\n      \"method\": \"HDAC6 knockout/inhibition, immunoprecipitation, in vitro deacetylase assay, H2O2 reduction activity assay, hyperoxidation resistance assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — identification of writer/eraser enzyme with functional activity assays and multiple readouts\",\n      \"pmids\": [\"18606987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Cytoplasmic Cdk5 is critically activated in stroke models (focal and global ischemia) in vivo, and PRDX2 (Prx2) is a critical cytoplasmic target of Cdk5; expression of dominant-negative Cdk5 localized to the cytoplasm is neuroprotective, and manipulation of Prx2 modulates neuronal survival after ischemic insult, establishing the calpain→Cdk5→Prx2 phosphorylation axis in ischemic neuronal death.\",\n      \"method\": \"Focal and global stroke mouse models, compartment-specific dominant-negative Cdk5 constructs, subcellular fractionation, Prx2 manipulation, neuronal death quantification\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo epistasis with compartmentalized constructs, multiple ischemia models\",\n      \"pmids\": [\"19812325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In human erythrocytes, PRDX2 (PrxII) exists in four distinct oligomeric states in the cytosol: a 440 kDa hetero-oligomeric complex with tetrameric catalase, and homo-polymeric complexes at 140, 100, and 67 kDa. Under oxidative stress (28-day storage), the 100 kDa complex disappears, the catalase-PrxII complex shifts to 480 kDa (incorporating cross-linked hemoglobin), and oxidized PrxII translocates to the membrane. Peroxidase activity was demonstrated for the 440 kDa and 140 kDa oligomers.\",\n      \"method\": \"Native proteomics (2D-DIGE, BN-PAGE), mass spectrometry, size-exclusion chromatography, peroxidase activity assay, fractionation of cytosol vs. membrane\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal proteomics methods identifying novel complex with activity validation\",\n      \"pmids\": [\"21354257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PRDX2 forms a redox relay with transcription factor STAT3: PRDX2 acts as an H2O2 signal receptor (reacting at ~10^7–10^8 M^-1 s^-1) and transmitter, oxidizing STAT3 via disulfide exchange to generate disulfide-linked STAT3 oligomers with attenuated transcriptional activity. Cytokine-induced STAT3 signaling is accompanied by co-oxidation of PRDX2 and STAT3, and is modulated by PRDX2 expression levels.\",\n      \"method\": \"Co-immunoprecipitation, non-reducing SDS-PAGE, in vitro redox reconstitution, siRNA knockdown/overexpression, cytokine stimulation, reporter assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution of relay, Co-IP, mutagenesis context, functional transcriptional readout replicated across multiple approaches\",\n      \"pmids\": [\"25402766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Inflammatory stimuli (LPS) induce release of glutathionylated PRDX2 from macrophages; extracellular glutathionylated PRDX2 acts as a redox-dependent danger signal triggering macrophages to produce TNF-α. PRDX2 is constitutively present intracellularly in reduced form and is released in oxidized (glutathionylated) form upon LPS stimulation. Co-released thioredoxin enables an oxidative cascade modifying surface receptor -SH groups to facilitate inflammatory activation.\",\n      \"method\": \"Mass spectrometry proteomic identification of glutathionylated proteins in LPS-stimulated macrophage conditioned medium, ELISA for TNF-α, Western blot, LPS stimulation of multiple cell types\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — MS identification of specific modification plus functional cytokine readout across multiple cell types\",\n      \"pmids\": [\"25097261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Peroxynitrite-mediated nitration of PRDX2 on non-catalytic tyrosines causes the reduced nitrated enzyme to adopt a conformation resembling the disulfide-oxidized native form, facilitating disulfide bond formation; this structural change explains the previously observed increase in peroxidase activity and resistance to overoxidation of nitrated PRDX2.\",\n      \"method\": \"Analytical ultracentrifugation, UV absorption, circular dichroism, steady-state and time-resolved fluorescence of recombinant human PRDX2\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple biophysical methods on purified protein with structural-functional correlation\",\n      \"pmids\": [\"26612102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Among interphase CDKs, CDK2 is specifically degraded via ubiquitin-proteasome pathway (with KLHL6 as E3 ligase) during AML differentiation; CDK2 depletion reactivates the differentiation pathway in part by reducing its direct maintenance of PRDX2 activity. The CDK2-PRDX2 axis maintains the differentiation block in AML cells.\",\n      \"method\": \"Yeast 2-hybrid (CDK2-KLHL6 interaction), ubiquitination assays, CDK2 inhibition/knockdown, AML differentiation assays (cell lines and primary patient samples), PRDX2 activity measurement, xenograft mouse models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — yeast 2-hybrid plus functional analysis, but CDK2-PRDX2 direct mechanism not biochemically reconstituted\",\n      \"pmids\": [\"29720484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Kinetic analysis shows that PRDX2 (unlike PRDX1) has a slow rate of intramolecular disulfide formation during catalytic cycle (0.2 s^-1 vs 11 s^-1 for PRDX1), creating a longer-lived sulfenic acid intermediate; this kinetic pause allows PRDX2's peroxidatic cysteine sulfenic acid to react with other protein thiols to transmit redox signals via mixed disulfides, differentiating its signaling role from PRDX1.\",\n      \"method\": \"In vitro kinetics using recombinant human PRDX1 and PRDX2, intrinsic fluorescence monitoring of oxidation and hyperoxidation with H2O2 and peroxynitrite\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — rigorous in vitro kinetics with purified recombinant proteins establishing mechanistic distinction\",\n      \"pmids\": [\"30284335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Radioprotective effects of exogenous recombinant PRDX2 in X-ray-irradiated animals are mediated by its peroxidase activity, its chaperone activity in the oxidized state (preventing protein misfolding and aggregation), and signal-regulatory functions via H2O2 level modulation; exogenous PRDX2 reduces ROS, suppresses apoptosis, prevents leukopenia/thrombocytopenia, and protects bone marrow DNA.\",\n      \"method\": \"Whole-body X-ray irradiation in vivo model, recombinant PRDX2 administration, survival studies, ROS measurement, apoptosis assays, bone marrow DNA damage assays\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo model with multiple phenotypic readouts, single lab\",\n      \"pmids\": [\"30605715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DNMT3A-R882H/C mutations in AML upregulate PRDX2 expression through promoter hypomethylation; elevated PRDX2 decreases ROS accumulation and reduces apoptosis, promoting leukemogenesis. Both DNMT3A-WT and R882H/C mutants physically interact with PRDX2. Knockdown of PRDX2 from DNMT3A-mutant myeloid cells restores drug sensitivity and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation (DNMT3A-PRDX2 interaction), DNA methylation assay, gene expression profiling, PRDX2 knockdown, ROS measurement, apoptosis assays\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP plus functional knockdown, single lab\",\n      \"pmids\": [\"30245403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"REV7, the structural subunit of DNA polymerase ζ, interacts with PRDX2 and recruits it to nuclear foci at DNA double-strand breaks post-irradiation; REV7 knockdown disrupts nuclear PRDX2 localization, causing increased oxidative stress and unrepaired DSBs, establishing a REV7-PRDX2 complex that confers radioresistance by protecting against oxidative stress at DSBs.\",\n      \"method\": \"Proteomic analysis of REV7-interacting proteins, co-immunoprecipitation, immunofluorescence co-localization, REV7 knockdown/overexpression, ROS measurement, γH2AX (DSB) assay, xenograft model\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP plus co-localization plus functional knockdown with mechanistic readout\",\n      \"pmids\": [\"30657231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"H. pylori infection activates NF-κB which transcriptionally upregulates PRDX2 (NF-κB-p65 binding site on PRDX2 promoter confirmed by luciferase reporter and ChIP assays); PRDX2 knockdown in gastric cancer cells increases ROS, oxidative DNA damage, and double-strand breaks in response to H. pylori, and sensitizes cells to cisplatin treatment.\",\n      \"method\": \"Luciferase reporter assay, ChIP assay, PRDX2 knockdown (shRNA), H2DCFDA ROS assay, 8-oxoguanine, γH2AX, in vitro and in vivo H. pylori infection models\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP + reporter identifies transcriptional mechanism; functional KD with multiple molecular readouts replicated in vitro and in vivo\",\n      \"pmids\": [\"31536951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRDX2 removal in colorectal cancer cells by shRNA inhibits S-phase progression and induces autophagy via the p38 MAPK/FOXO signaling pathway; the p38 activator dehydrocorydaline partially rescues cell-cycle and autophagy effects of PRDX2 knockdown, placing PRDX2 upstream of p38 MAPK in cell-cycle control.\",\n      \"method\": \"shRNA knockdown, flow cytometry (cell cycle), electron microscopy (autophagy), Western blot (p38 activation), immunostaining, p38 activator rescue, xenograft mouse model\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — shRNA with epistasis rescue and multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"32692719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRDX2 overexpression in H9c2 cardiomyocytes promotes TLR4-mediated inflammatory factor expression (IL-1β, TNF-α, IL-6) and VEGF expression under hypoxia while inhibiting ROS-mediated injury, demonstrating a dual role: cytoprotective (ROS scavenging) and pro-inflammatory (via TLR4 pathway activation).\",\n      \"method\": \"PRDX2 overexpression in H9c2 cells, AMI mouse model, ELISA, immunocytochemistry, immunofluorescence, ROS measurement\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — overexpression with mechanistic pathway identification, single lab\",\n      \"pmids\": [\"28765537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRDX2 inhibits TLR4/NF-κB signaling in myocardial cells after acute myocardial infarction: recombinant PRDX2 treatment in AMI rats decreases ROS, reduces caspase-family expression, inhibits p65 phosphorylation, and suppresses TLR4/NF-κB pathway activity, reducing myocardial apoptosis.\",\n      \"method\": \"AMI rat model (LAD ligation), recombinant PRDX2 administration, Western blot, qRT-PCR, ROS assay\",\n      \"journal\": \"Medical science monitor\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo model with recombinant protein and pathway measurement, single lab\",\n      \"pmids\": [\"33268762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CircDIDO1 specifically binds PRDX2 protein and promotes RBX1-mediated ubiquitination and proteasomal degradation of PRDX2, leading to inactivation of PRDX2 downstream signaling pathways; this reduces gastric cancer cell proliferation, migration, and invasion.\",\n      \"method\": \"Tagged RNA affinity purification, mass spectrometry, co-immunoprecipitation, immunofluorescence, Western blot, gain/loss-of-function studies, xenograft mouse models\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — RNA-protein interaction identified by TRAP-MS + Co-IP ubiquitination validation, single lab\",\n      \"pmids\": [\"34384442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PRDX2 overexpression in vascular smooth muscle cells reduces ROS (H2O2), collagen I/III, VCAM-1, and ICAM-1 expression, and inhibits VSMC proliferation, migration, and phenotype transformation; PRDX2 suppresses p-p38, p-JNK, and p-ERK activation (MAPK pathway), providing protection against atherosclerosis. MAPK inhibitor treatment confirmed the mechanistic link.\",\n      \"method\": \"PRDX2 overexpression/siRNA knockdown in CAVSMCs, MAPK inhibitors (SB203580, SP600125, PD98059), proliferation/migration assays, Western blot, immunostaining\",\n      \"journal\": \"Frontiers in cardiovascular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological epistasis plus gain/loss of function, single lab\",\n      \"pmids\": [\"33791345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Oxiconazole downregulates PRDX2 protein levels to initiate autophagy in colorectal cancer cells by inactivating the Akt/mTOR pathway and inhibiting RAB7A-mediated autophagosome-lysosome fusion, causing extreme accumulation of autophagosomes; PRDX2 overexpression rescues OXI-induced autophagy arrest, establishing PRDX2 as a critical node upstream of Akt/mTOR in autophagy regulation.\",\n      \"method\": \"Drug treatment, PRDX2 overexpression rescue, autophagy flux assays, Akt/mTOR pathway Western blot, RAB7A analysis, CRC xenograft model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — overexpression rescue establishes causal mechanism, single lab\",\n      \"pmids\": [\"35813474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Dihydromyricetin (DHM) induces neuroprotection after subarachnoid hemorrhage through a Nrf2-dependent increase in PRDX2 expression that decreases phosphorylation of p38 and ASK1; siRNA knockdown of Prx2 or Nrf2 inhibition with ML385 attenuates DHM's neuroprotective effects, placing PRDX2 downstream of Nrf2 in the anti-oxidative cascade triggered by DHM.\",\n      \"method\": \"SAH rat model, siRNA knockdown of Prx2, Nrf2 inhibitor ML385, neurological behavioral tests, ROS assay, Western blot, immunofluorescence, primary cortical neurons in vitro\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo + in vitro epistasis with siRNA and pharmacological inhibitor, single lab\",\n      \"pmids\": [\"37523836\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRDX2 is a cytosolic typical 2-Cys peroxidase that forms a decameric toroid of five homodimers and scavenges H2O2 with exceptionally high reactivity (~10^7 M^-1 s^-1) via its peroxidatic Cys51; its slower intramolecular disulfide formation rate (vs. PRDX1) prolongs the sulfenic acid intermediate, enabling it to transmit redox signals through mixed disulfides to partners such as STAT3, and its activity is regulated by multiple PTMs including Cdk5-mediated phosphorylation at Thr89 (inactivating), HDAC6-dependent deacetylation (modulating activity/overoxidation resistance), and peroxynitrite-mediated tyrosine nitration (activating); it is recruited to PDGFR to locally suppress H2O2-dependent signaling, released as glutathionylated PRDX2 to trigger inflammatory TNF-α responses, and its oxidized form exhibits chaperone activity, while overoxidized PRDX2 is regenerated by p53-regulated sestrins.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRDX2 is a typical 2-Cys peroxiredoxin that eliminates hydrogen peroxide and functions as both a peroxidase and an oxidation-state-dependent molecular chaperone, serving as a central node linking cellular redox homeostasis to signaling, differentiation, apoptosis, and DNA damage responses. Its catalytic cycle involves rapid oxidation of the peroxidatic cysteine to a sulfenic acid intermediate, but an unusually slow disulfide resolution step (0.2 s⁻¹) prolongs sulfenic acid lifetime, enabling redox relay to partner protein thiols rather than simple H₂O₂ scavenging [PMID:30284335]. PRDX2 peroxidase activity is negatively regulated by Cdk5-mediated phosphorylation at T89 — a pathway activated by calpain during mitochondrial stress and ischemia that increases neuronal ROS and death — and is positively maintained by CDK2 in myeloid leukemia cells where its loss triggers ROS-dependent granulocytic differentiation [PMID:17610816, PMID:29720484]. PRDX2 stability is controlled by ubiquitin–proteasome pathways modulated by RNA partners (circDIDO1 promotes RBX1-mediated degradation; CASC15 lncRNA prevents degradation), and its depletion derepresses p38 MAPK and suppresses PI3K/AKT/mTOR signaling to alter cell-cycle progression, autophagy, and apoptosis [PMID:34384442, PMID:33017884, PMID:32692719, PMID:28432271].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Establishing that PRDX2 functions as a bona fide neuronal antioxidant enzyme answered whether this peroxiredoxin family member is required for oxidative stress defense in mammalian cells.\",\n      \"evidence\": \"Stable antisense knockdown in neuroblastoma cells increased sensitivity to oxidative cytotoxic agents and basal apoptosis\",\n      \"pmids\": [\"12943237\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No catalytic mechanism or rate constants defined\", \"Single cell line, no in vivo confirmation\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"PRDX2 knockout mice revealed that PRDX2-dependent ROS levels regulate thymocyte apoptosis and development, establishing an in vivo physiological role beyond generic antioxidant defense.\",\n      \"evidence\": \"PrxII-null mice showed thymic enlargement, elevated thymocyte ROS, and resistance to apoptosis induced by dexamethasone or food restriction\",\n      \"pmids\": [\"15259009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling mediators of ROS-driven thymocyte survival not identified\", \"Whether the phenotype reflects peroxidase versus chaperone function unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of Cdk5-mediated phosphorylation at T89 as a negative regulator of PRDX2 peroxidase activity established the first post-translational regulatory mechanism and connected PRDX2 inactivation to dopaminergic neurodegeneration.\",\n      \"evidence\": \"Biochemical phosphorylation assays, T89A/T89E mutagenesis, activity assays, MPTP mouse model, and postmortem Parkinson's disease tissue\",\n      \"pmids\": [\"17610816\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for how T89 phosphorylation inhibits catalysis not resolved\", \"Whether other kinases target T89 in non-neuronal cells unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrating that cytoplasmic Cdk5 phosphorylates and inactivates PRDX2 in ischemia models generalized the Cdk5–PRDX2 axis beyond Parkinson's disease to stroke.\",\n      \"evidence\": \"Compartment-specific dominant-negative Cdk5 constructs in focal and global ischemia models\",\n      \"pmids\": [\"19812325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether therapeutic targeting of T89 phosphorylation is feasible remains untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Discovery that PRDX2 forms a 440 kDa hetero-oligomeric complex with tetrameric catalase in erythrocytes revealed that PRDX2 operates within defined multiprotein ROS-scavenging complexes rather than solely as a homodimer.\",\n      \"evidence\": \"Native gel electrophoresis, mass spectrometry, and peroxidase activity assays on isolated oligomeric fractions from human erythrocytes\",\n      \"pmids\": [\"21354257\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Stoichiometry and interface of the PRDX2–catalase complex not structurally defined\", \"Functional advantage of the hetero-complex over individual enzymes not quantified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Structural analysis of peroxynitrite-nitrated PRDX2 showed that tyrosine nitration mimics the disulfide-oxidized conformation, explaining enhanced peroxidase activity and resistance to overoxidation — a second layer of PTM-based regulation.\",\n      \"evidence\": \"Analytical ultracentrifugation, circular dichroism, and time-resolved fluorescence of recombinant PRDX2 after peroxynitrite treatment\",\n      \"pmids\": [\"26612102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of nitration-mediated activation not demonstrated\", \"Specific nitrated tyrosine residues not mapped to individual functional effects\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Quantitative kinetic characterization revealed that PRDX2's disulfide resolution rate is ~55-fold slower than PRDX1, prolonging its sulfenic acid intermediate and enabling redox relay to partner thiols — distinguishing PRDX2 as a signal transducer rather than just a scavenger.\",\n      \"evidence\": \"Intrinsic fluorescence-based kinetics of recombinant human PRDX2 vs PRDX1 with H₂O₂ and peroxynitrite at pH 7.4\",\n      \"pmids\": [\"30284335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of physiological thiol relay partners not determined\", \"Whether the slow resolution rate is conserved across species unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Multiple 2018 studies expanded PRDX2 regulation and function: CDK2 was identified as a positive upstream regulator maintaining PRDX2 activity to block myeloid differentiation; DNMT3A mutations were shown to upregulate PRDX2 via promoter hypomethylation in AML; and oxidized PRDX2 was shown to possess chaperone activity protecting against radiation damage in vivo.\",\n      \"evidence\": \"Yeast two-hybrid and CDK2 knockdown in AML cells/xenografts; methylation and Co-IP studies of DNMT3A–PRDX2; in vitro chaperone assays plus whole-body irradiation mouse model\",\n      \"pmids\": [\"29720484\", \"30245403\", \"30605715\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which CDK2 maintains PRDX2 activity (phosphorylation site, direct vs indirect) not defined\", \"Relative contribution of chaperone vs peroxidase activity in radioprotection unclear\", \"Each finding from a single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"REV7 was identified as a partner that recruits PRDX2 to the nucleus and to DNA double-strand break sites, connecting PRDX2 to DNA damage repair and radioresistance — a function outside its canonical cytoplasmic antioxidant role.\",\n      \"evidence\": \"Proteomic identification, co-immunoprecipitation, immunofluorescence co-localization at DSBs, REV7 knockdown phenotyping\",\n      \"pmids\": [\"30657231\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PRDX2 acts enzymatically at DSBs or structurally is unknown\", \"No reconstitution of PRDX2 peroxidase activity at break sites\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"NF-κB-p65 was shown to directly bind the PRDX2 promoter and transcriptionally upregulate PRDX2 during H. pylori infection, establishing a transcriptional regulatory input and linking PRDX2 to defense against infection-induced oxidative DNA damage.\",\n      \"evidence\": \"ChIP and luciferase reporter assays on the PRDX2 promoter, PRDX2 knockdown with ROS and γ-H2AX readouts in H. pylori-infected cells\",\n      \"pmids\": [\"31536951\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether other NF-κB family members contribute to PRDX2 regulation not tested\", \"Relevance to gastric carcinogenesis not directly demonstrated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"PRDX2 depletion was shown to activate p38 MAPK/FOXO signaling and suppress PI3K/AKT in colorectal cancer, establishing PRDX2 as a gatekeeper of multiple oncogenic signaling cascades through ROS modulation.\",\n      \"evidence\": \"shRNA knockdown with p38 activator rescue, Western blotting, autophagy flux assays, xenograft models; complementary gain/loss-of-function for PI3K/AKT\",\n      \"pmids\": [\"32692719\", \"28432271\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular target linking PRDX2-derived ROS to p38 activation not identified\", \"Whether these pathways are engaged simultaneously or context-dependently unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CircDIDO1 was identified as a direct PRDX2-binding RNA that promotes RBX1-mediated ubiquitination and proteasomal degradation of PRDX2, revealing a non-coding RNA layer of PRDX2 protein stability control.\",\n      \"evidence\": \"Tagged RNA affinity purification, mass spectrometry, co-immunoprecipitation, ubiquitination assays, mouse tumor models\",\n      \"pmids\": [\"34384442\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How circDIDO1 binding exposes PRDX2 to RBX1-mediated ubiquitination mechanistically undefined\", \"Specific ubiquitinated lysines on PRDX2 not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Pharmacological downregulation of PRDX2 by oxiconazole was shown to increase ROS, inactivate Akt/mTOR, and block RAB7A-mediated autophagosome–lysosome fusion, extending the PRDX2–Akt axis to autophagy regulation.\",\n      \"evidence\": \"PRDX2 overexpression rescue, Akt/mTOR Western blotting, autophagy flux assays, RAB7A analysis in CRC cells\",\n      \"pmids\": [\"35813474\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PRDX2 affects RAB7A directly or only via Akt/mTOR signaling not resolved\", \"Mechanism of oxiconazole-induced PRDX2 downregulation not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of physiological thiol relay partners that receive oxidizing equivalents from the long-lived PRDX2 sulfenic acid, the structural basis for T89 phosphorylation-mediated inactivation, the mechanism by which CDK2 maintains PRDX2 activity, and the relative contributions of peroxidase versus chaperone activities in different physiological and disease contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No sulfenic acid relay partner identified in cells\", \"No crystal structure of T89-phosphorylated PRDX2\", \"Chaperone vs peroxidase contributions not genetically separated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [0, 7, 8, 9, 10, 11, 16]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [7, 8, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 7, 10, 11]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [12, 13, 14, 15]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 1, 7, 9, 11, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 11, 12]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13, 15]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [4, 6]}\n    ],\n    \"complexes\": [\n      \"PRDX2–catalase hetero-oligomeric complex (440 kDa in erythrocytes)\"\n    ],\n    \"partners\": [\n      \"CDK5\",\n      \"CDK2\",\n      \"CAT\",\n      \"REV7\",\n      \"RBX1\",\n      \"DNMT3A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PRDX2 is a 2-Cys peroxiredoxin that scavenges hydrogen peroxide with exceptional selectivity and reactivity (~10⁷ M⁻¹ s⁻¹) and transduces H₂O₂ signals to downstream effectors through its unusually long-lived sulfenic acid intermediate [PMID:10873855, PMID:17329258, PMID:30284335]. Assembled as a decameric toroid of five homodimers, PRDX2 is recruited to activated PDGF receptor to locally suppress H₂O₂-dependent signaling, and oxidizes STAT3 via a disulfide relay that attenuates STAT3 transcriptional activity, while its glutathionylated form is released from macrophages as an inflammatory danger signal triggering TNF-α production [PMID:15902258, PMID:25402766, PMID:25097261]. PRDX2 activity is regulated by Cdk5-mediated Thr89 phosphorylation (inactivating, contributing to neuronal death in Parkinson's disease and ischemia), HDAC6-dependent deacetylation (modulating activity and overoxidation resistance), and peroxynitrite-mediated tyrosine nitration (activating), while overoxidized enzyme is regenerated by the p53-regulated sulfinyl reductase sestrin 2 [PMID:17610816, PMID:18606987, PMID:26612102, PMID:15105503]. In erythrocytes, PRDX2 operates as a stoichiometric H₂O₂ scavenger that forms a native complex with catalase, and its oxidized form exhibits molecular chaperone activity that prevents protein aggregation [PMID:17105810, PMID:21354257, PMID:30605715].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Determining the atomic structure of PRDX2 revealed how a decameric toroid architecture positions the catalytic Cys51 and requires large conformational rearrangements during catalysis, establishing the structural framework for understanding its peroxidase mechanism.\",\n      \"evidence\": \"1.7 Å X-ray crystal structure of human erythrocyte PRDX2 with sedimentation analysis\",\n      \"pmids\": [\"10873855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of the reduced active-site form was captured\", \"Dynamics of conformational transitions during catalysis unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of in vivo overoxidation of the active-site cysteine to cysteic acid revealed that irreversible inactivation of PRDX2 modulates susceptibility to TNF-α-induced apoptosis, establishing overoxidation as a functionally consequential event rather than an artifact.\",\n      \"evidence\": \"2D-gel proteomics and tandem MS in Leydig cells with apoptosis readout\",\n      \"pmids\": [\"11904290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking overoxidized PRDX2 to apoptotic threshold unknown\", \"Whether overoxidation gain-of-function (e.g., chaperone) contributes was not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Two discoveries resolved how PRDX2 overoxidation is reversed and what happens in its complete absence in vivo: sestrin 2 was identified as the ATP-dependent sulfinyl reductase that regenerates overoxidized PRDX2, while PRDX2-knockout mice revealed a non-redundant role in thymocyte apoptosis and immune homeostasis through ROS control.\",\n      \"evidence\": \"In vitro reconstitution with purified sestrin 2; PrxII-knockout mouse with FACS and apoptosis analysis\",\n      \"pmids\": [\"15105503\", \"15259009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other sestrins contribute in specific tissues was not addressed\", \"Molecular targets of elevated ROS in PRDX2-null thymocytes unidentified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstration that PRDX2 is recruited to PDGF receptor and locally eliminates H₂O₂ to suppress receptor signaling established the first paradigm for PRDX2 as a spatially targeted signaling modulator rather than merely a bulk antioxidant.\",\n      \"evidence\": \"Co-immunoprecipitation of PDGFR-PRDX2, Prdx2-knockout mouse, inactive-mutant control, murine restenosis model\",\n      \"pmids\": [\"15902258\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PRDX2 is recruited to PDGFR (adaptor, direct binding domain) uncharacterized\", \"Generalizability to other RTKs not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showing that erythrocyte PRDX2 operates as a stoichiometric H₂O₂ scavenger—exquisitely sensitive to oxidation yet resistant to overoxidation due to limiting thioredoxin reductase—resolved the paradox of how an abundant peroxiredoxin protects cells with negligible catalytic turnover.\",\n      \"evidence\": \"Non-reducing SDS-PAGE dimerization assay, thioredoxin reductase activity measurement in erythrocyte hemolysates\",\n      \"pmids\": [\"17105810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of stoichiometric scavenging vs. residual enzymatic turnover not fully delineated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Two advances defined PRDX2 substrate selectivity and a disease-relevant inactivation mechanism: kinetic measurements established ~10⁷ M⁻¹ s⁻¹ reactivity highly selective for H₂O₂ over other oxidants, while Cdk5-mediated Thr89 phosphorylation was identified as an inactivating modification that promotes dopaminergic neuron death, with elevated pThr89-PRDX2 detected in Parkinson's disease brain tissue.\",\n      \"evidence\": \"Competition kinetics with HRP; Co-IP of Prx2-Cdk5/p35, T89A/T89E mutagenesis, MPP+/MPTP model, p35-KO neurons, postmortem PD brain immunostaining\",\n      \"pmids\": [\"17329258\", \"17610816\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Thr89 phosphorylation occurs in non-neuronal contexts unknown\", \"Crystal structure of phospho-PRDX2 not determined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of HDAC6 as the specific deacetylase of PRDX2 revealed acetylation as a positive regulatory PTM that enhances peroxidase activity and resistance to overoxidation, adding a second layer of post-translational control beyond phosphorylation.\",\n      \"evidence\": \"HDAC6-knockout/inhibition, in vitro deacetylase assay, H₂O₂ reduction and hyperoxidation assays\",\n      \"pmids\": [\"18606987\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the acetyltransferase(s) responsible for PRDX2 acetylation unknown\", \"Specific acetylated lysine residues and their individual contributions unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extension of the calpain→Cdk5→PRDX2 phosphorylation axis to ischemic stroke models demonstrated that cytoplasmic Cdk5-mediated PRDX2 inactivation is a general mechanism of oxidative neuronal death, not restricted to dopaminergic toxins.\",\n      \"evidence\": \"Focal and global ischemia mouse models with compartment-specific dominant-negative Cdk5 and Prx2 manipulation\",\n      \"pmids\": [\"19812325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other cytoplasmic Cdk5 substrates contribute to ischemic death alongside PRDX2 not dissected\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Native proteomics revealed that erythrocyte PRDX2 exists in multiple oligomeric states including a functional 440 kDa hetero-complex with catalase, and that oxidative stress triggers membrane translocation of oxidized PRDX2, suggesting compartmentalized antioxidant networks.\",\n      \"evidence\": \"BN-PAGE, 2D-DIGE, size-exclusion chromatography, MS identification, peroxidase activity of isolated complexes\",\n      \"pmids\": [\"21354257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of membrane-translocated PRDX2 not established\", \"Whether the catalase-PRDX2 complex exists in nucleated cells unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Two studies established PRDX2 as a bona fide redox signal transducer: it oxidizes STAT3 via disulfide relay to attenuate STAT3 transcriptional activity, and it is released as glutathionylated PRDX2 from LPS-stimulated macrophages to trigger TNF-α-mediated inflammation, demonstrating both intracellular and extracellular signaling functions.\",\n      \"evidence\": \"In vitro redox reconstitution of PRDX2-STAT3 relay with reporter assays; MS identification of glutathionylated PRDX2 in macrophage secretome with TNF-α ELISA\",\n      \"pmids\": [\"25402766\", \"25097261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of PRDX2 relay partners beyond STAT3 not mapped\", \"Receptor mediating extracellular glutathionylated PRDX2 signaling not identified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Biophysical analysis showed that peroxynitrite-mediated tyrosine nitration shifts reduced PRDX2 into a conformation resembling the disulfide-oxidized form, mechanistically explaining the observed increase in peroxidase activity upon nitration.\",\n      \"evidence\": \"Analytical ultracentrifugation, CD, steady-state and time-resolved fluorescence of recombinant PRDX2\",\n      \"pmids\": [\"26612102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of nitrated PRDX2 not demonstrated\", \"Specific nitrated tyrosine residues responsible not individually mutated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The kinetic basis for PRDX2's superior signaling capacity was established: its intramolecular disulfide forms 55-fold slower than PRDX1's (0.2 vs. 11 s⁻¹), prolonging the sulfenic acid intermediate available for mixed-disulfide transfer to signaling partners.\",\n      \"evidence\": \"In vitro kinetics with recombinant PRDX1 and PRDX2, intrinsic fluorescence monitoring\",\n      \"pmids\": [\"30284335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for the slow resolution rate not determined\", \"Whether the prolonged sulfenic acid reacts with specific partners preferentially not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"REV7 was identified as a partner that recruits PRDX2 to nuclear DNA double-strand break foci, revealing a previously unrecognized nuclear antioxidant function at DNA damage sites that contributes to radioresistance.\",\n      \"evidence\": \"Proteomics of REV7 interactors, Co-IP, immunofluorescence co-localization, REV7 knockdown with γH2AX and ROS assays\",\n      \"pmids\": [\"30657231\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical reconstitution of REV7-PRDX2 interaction not performed\", \"Whether PRDX2 peroxidase activity vs. chaperone activity is relevant at DSBs unknown\", \"Single lab finding not independently confirmed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Multiple studies positioned PRDX2 as a signaling node upstream of MAPK pathways: PRDX2 depletion activates p38 MAPK/FOXO to arrest cell cycle and induce autophagy in colorectal cancer, while PRDX2 overexpression suppresses p38/JNK/ERK in vascular smooth muscle cells, establishing MAPK suppression as a conserved downstream consequence of PRDX2 activity.\",\n      \"evidence\": \"shRNA knockdown with p38 activator rescue and xenograft model; overexpression/siRNA with MAPK inhibitor epistasis in VSMCs\",\n      \"pmids\": [\"32692719\", \"33791345\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PRDX2 acts on MAPKs through direct H₂O₂ scavenging or specific protein interactions not distinguished\", \"Cell-type specificity of MAPK branch preference unexplored\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"PRDX2 was placed upstream of Akt/mTOR signaling: oxiconazole-induced PRDX2 depletion inactivated Akt/mTOR and caused autophagic arrest, while PRDX2 overexpression rescued, establishing PRDX2 as a regulator of autophagy flux via the Akt/mTOR axis.\",\n      \"evidence\": \"Drug-induced PRDX2 depletion with overexpression rescue, autophagy flux assays, Akt/mTOR pathway analysis in CRC xenograft\",\n      \"pmids\": [\"35813474\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between PRDX2 and Akt activation not identified\", \"Whether this involves redox modification of Akt pathway phosphatases unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full repertoire of PRDX2 sulfenic-acid relay partners beyond STAT3, the receptor mediating extracellular glutathionylated PRDX2 inflammatory signaling, the structural basis for PRDX2's slow disulfide resolution that favors signal transmission, and how PRDX2 is spatially recruited to specific signaling complexes (PDGFR, DSB foci).\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Comprehensive mapping of PRDX2 sulfenic acid interactome not performed\", \"No structural model of the PRDX2-STAT3 relay complex\", \"Mechanism of PRDX2 recruitment to PDGFR and DNA damage foci undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016209\", \"supporting_discovery_ids\": [0, 1, 6, 7, 12, 16]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 7, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 12, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 6, 10, 11]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [11]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 12, 21, 25]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [1, 6, 7, 14, 16]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 13, 22]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 2, 8, 23]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [21, 26]}\n    ],\n    \"complexes\": [\n      \"PRDX2 decameric toroid (five homodimers)\",\n      \"PRDX2-catalase hetero-oligomeric complex (erythrocyte)\"\n    ],\n    \"partners\": [\n      \"STAT3\",\n      \"PDGFRB\",\n      \"CDK5\",\n      \"HDAC6\",\n      \"SESN2\",\n      \"MAD2L2\",\n      \"DNMT3A\",\n      \"CAT\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}